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This review aims to create an overview of the currently available results of site-directed mutagenesis studies on
transient receptor potential vanilloid type 1 (TRPV1) receptor. Systematization of the vast number of data on the
functionally important amino acid mutations of TRPV1 may provide a clearer picture of this field, and may promote
a better understanding of the relationship between the structure and function of TRPV1. The review summarizes
information on 112 unique mutated sites along the TRPV1, exchanged to multiple different residues in many cases.
These mutations influence the effect or binding of different agonists, antagonists, and channel blockers, alter the
responsiveness to heat, acid, and voltage dependence, affect the channel pore characteristics, and influence the
regulation of the receptor function by phosphorylation, glycosylation, calmodulin, PIP2, ATP, and lipid binding.
The main goal of this paper is to publish the above mentioned data in a form that facilitates in silico molecular
modelling of the receptor by promoting easier establishment of boundary conditions. The better understanding of
the structure-function relationship of TRPV1 may promote discovery of new, promising, more effective and safe
drugs for treatment of neurogenic inflammation and pain-related diseases and may offer new opportunities for
therapeutic interventions.
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This review aims to create an overview of the currently
available results of site-directed mutagenesis studies on
transient receptor potential vanilloid type 1 (TRPV1) re-
ceptor. Systematization of the vast number of data on
the functionally important amino acid mutations of
TRPV1 may provide a clearer picture of this field, and
may promote a better understanding of the relationship
between the structure and function of TRPV1.
The first few sections provide a brief introduction of
the transient receptor potential family and the TRPV1
ion channel. The following sections compile the posi-
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reproduction in any medium, provided the oramino acid changes of these 112 unique mutated sites of
TRPV1. The information collected in this form may
serve as a powerful tool for in silico molecular modelling
by facilitating the establishment of boundary conditions.
All mutations and positions discussed in this paper
generally refer to the rat ortholog (rTRPV1) of the
TRPV1. All results relating to other species will be
highlighted in the text.
Transient receptor potential channels
The first TRP channel was discovered in 1969 by Cosens
and Manning, who isolated a mutant photoreceptor from
Drosophila melanogaster, which caused the specimen to
become temporally blind upon exposure to bright light
[1,2]. TRP channels are one of the largest families of ion
channels. The mammalian TRP superfamily consisting of
28 TRP cation channels can be subdivided into sixLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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TRPM (“Melastatin”), TRPP (“Polycystin”), TRPML
(“MucoLipin”) and the TRPA (“Ankyrin”) groups [3,4].
All TRP channels are tetramers assembled with four-
fold symmetry from the individual subunits containing
six putative transmembrane segments (TMs). The region
between the fifth and the sixth TMs, including a putative
pore loop, forms the ion permeation pathway [5]. The
amino and carboxyl (N- and C-) termini are located
intracellularly and vary vastly in length and amino acid
sequence. These cytoplasmic regions contain diverse well-
recognized domains and motifs that are likely to be involved
in channel assembly, activation and regulation through
protein-protein and/or protein-ligand interactions. Most
TRP channels are cation-selective, and some are highly se-
lective for Ca2+ or Mg2+ [4]. In accordance with their amino
acid sequence diversity, TRP channels exhibit various acti-
vation and modulatory mechanisms, such as those involv-
ing in the stimulation by G-protein-coupled receptors,
extracellular and intracellular ligands (including H+, Ca2+
and Mg2+), phosphatidylinositol-4,5-bisphosphate (PIP2),
temperature, and mechanical stretch [6].
The accumulating evidence that TRP channels are im-
portant components of several human diseases has cre-
ated a huge interest for these channels as novel potential
drug targets. Comprehensive reviews have been pub-
lished on the modulation and potential pharmaceutical
application of TRP channels [7-11].
TRPV subfamily
The TRPV family includes six mammalian ion channels,
TRPV1-TRPV6, with a large C- and an even larger N-
terminal cytoplasmatic domain containing ankyrin repeat
domains (ARD) [12,13]. Ankyrin repeats, the 33-residue
sequence motifs, are essential in channel function, ATP,
PIP2, and calmodulin (CaM) binding [14] and protein-
protein interactions [15,16]. They are present in many
proteins, with functions including signalling, cytoskeleton
integrity, transcription and cellular localization [17,18].
As polymodal thermo- and chemosensitive channels,
TRPV1-TRPV4 are non-selective for cations and modestly
permeable to Ca2+. In contrast, TRPV5 and TRPV6 are
the only highly Ca2+-selective channels in the TRP family,
and both channels are tightly regulated by the intracellular
Ca2+ concentration [10,19,20].
TRPV channels can be activated through a variety of
mechanisms. TRPV1-TRPV4 can act as thermosensors
at a molecular level. Interestingly, each of these channels
has a different thermal threshold for activation. When
expressed in transfected permanent cell lines (HEK293
and CHO cells) and in frog oocytes [4,21,22], TRPV2,
TRPV1, TRPV3 and TRPV4 are activated at 52°C , 43°C,
33°C, and below 33°C, respectively. The TRPV family
members, except for TRPV1, are insensitive to vanilloidcompounds [4]. TRPV3 can be activated by essential oils
from clove (eugenol), thyme (thymol) and oregano (car-
vacrol) [23]. Like TRPV1, TRPV3 is also activated by
camphor [24]. TRPV4 can be activated by cell swelling
caused by 5',6'-epoxyeicosatrienoic acid [25]. TRPV5 and
TRPV6, originally named ECaC [26] and CAT1 [27], are
Ca2+ entry channels responsible for Ca2+ absorption in
the kidney and intestine, respectively.
TRPV1
In 1997, the breakthrough work of Michael Caterina and
colleagues in the field of somatic sensory biology and pain
research led to the cloning of the vanilloid (capsaicin) re-
ceptor, TRPV1 [28]. The cloning of TRPV1 proved to be a
significant step in the understanding of molecular mecha-
nisms that underlie the transduction of noxious thermal
and chemical stimuli by sensory neurones [9].
Characteristics of TRPV1
As a TRPV subfamily member, TRPV1 can be character-
ized by some key properties that are common among the
members of the family. It is built from four individual sub-
units containing six TMs [29]. TRPV1 has a pore-forming
hydrophobic stretch between TM5 and TM6 and is be-
lieved to exist as a homo- or heteromeric complex form
[28-30] (Figure 1).
The TRPV1 receptor is a non-selective ligand-gated
cation channel with a ninefold higher permeability for
Ca2+ than for Na+. It is an integrator of a wide variety of
exogenous and endogenous physical and chemical stim-
uli, including capsaicin (CAPS), noxious heat (>43°C)
and protons (pH<5.2). Strictly speaking, CAPS and its
biological analogs isolated from plants and animals are
essentially sensitizers, because they act by lowering the
thermal “physiological” activation threshold of TRPV1.
Nevertheless, because these compounds bind directly to
TRPV1, they are conveniently considered as direct acti-
vators, in contrast to compounds that do not bind
TRPV1 and affect its functioning indirectly, which are
referred to as sensitizers [31]. Besides CAPS, many com-
plex amphiphilic molecules have been shown to activate
or inhibit TRPV1. These include polyring compounds
such as resiniferatoxin (RTX), a highly irritant diterpene
related to the phorbol esters [32] which is almost 20-
fold more potent than CAPS [33]. Species-specific differ-
ences in RTX potency have also been described, for ex-
ample, RTX is a more potent agonist on rTRPV1 than
its human ortholog (hTRPV1) [34,35]. Further molecules
with similar structures, such as quinazolinone [36],
evodiamine [37] and 17-β-estradiol [38], as well as mole-
cules with long acyl and amide chains, such as ananda-
mide [39-45], olvanil and omega-3 polyunsaturated fatty
acids can also activate the channel [46]. Other natural
TRPV1 agonists are 12-hydroperoxyeicosatetraenoic acid
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[42,47-49]. Piperine from black pepper, eugenol from
cloves and zingerone from ginger have also been shown to
activate TRPV1 [50,51]. Additionally, gingerols, present in
raw ginger, and shogaols, which are dehydration products
of gingerols present in steamed ginger, both of which pos-
sess a vanillyl moiety, also activate TRPV1 [35,45,52,53].
Since both CAPS and its analogues are lipophilic, they are
able to cross the cell membrane and act on binding sites
present on the intracellular surface of TRPV1 [54]. TRPV1
can also be activated by 2-aminoethoxydiphenyl borate
(2-APB). 2-APB inhibits both IP3 receptors and the ma-
jority of TRP channels, though at higher concentrations it
activates TRPV1, TRPV2 and TRPV3 [11,55]. There has
been debates about whether TRPV1 can [56-59] or can
not [60-63] be activated by AITC. Stimuli are detected
and transduced through opening of the ion channel,
which results in the entry of cations such as Ca2+ and Na+
to the neurone [28]. Due to its uniqueness in its diverse
operational features, which differ from the classical, more
restrained proteins of voltage-gated and ligand-gated
channels, as well as from the G-protein-coupled receptors,
TRPV1 was dubbed “multisteric nocisensor” in the recent
review paper by Szolcsányi and Sándor [64].
The inorganic dye Ruthenium Red (RuRed), is used in
histology to stain aldehyde fixed mucopolysaccharides.
Long before the cloning of TRPV1 RuRed was demon-
strated to be able to inhibit CAPS-induced responses in
sensory neurones [65]. Later it was shown that RuRed is
a non-competitive antagonist not only for TRPV1 but
for most other TRP channels functioning as a pore
blocker [31]. The first competitive antagonist identified
for TRPV1 was the CAPS analogue capsazepine (CapZ).
CapZ is a relative potent antagonist on hTRPV1 but
demonstrated much less potency on rTRPV1 [66,67], il-
lustrating the differences between species that is com-
mon for many TRPV1 antagonists. Since the discovery
of CapZ the number of TRPV1 patents has exceeded
1,000. Most of these antagonists show high affinity to
TRPV1 and are competitive antagonists binding to the
same site as CAPS and many of them have also demon-
strated in vivo effects in various pain models [68]. The
halogenated version of RTX, iodoresiniferatoxin (I-RTX)
has been identified as a high-affinity antagonist of the
TRPV1 channel and similarly to RTX, it also exert differ-
ent potency on the hTRPV1 and rTRPV1 [69]. R4W2, a
small positively charged peptide was identified to be
non-competitive antagonist blocker of recombinant
TRPV1 channels expressed in Xenopus oocytes [70],
blocking CAPS-operated ionic currents with micromolar
efficacy in a weakly voltage-dependent manner. R4W2
was later found to be competitive antagonist of TRPV1
also in primary cultures of adult rat dorsal root ganglion
neurons (DRGs) [71].Besides its involvement in pain sensation, TRPV1 dis-
plays a low level of activity at normal body temperature
[72,73]. Constitutive activity of TRPV1 is essential for
regulation of body temperature, evidenced by high fever as
a adverse side effect of many TRPV1 blockers during clin-
ical trials for their efficacy in management or prophylaxis
of pain [74,75]. Moreover, at room temperature (24°C) and
pH 7.3, TRPV1 behaves as a voltage-gated outwardly recti-
fying channel, since it can be activated, in the absence of
any agonist, by depolarizing voltages (> +60 mV) [76].
One striking feature of TRPV1 is that the receptor can
be sensitized and desensitized. This fact suggests that
the TRPV1 function is subject to extensive modulation,
which has significant implications for the involvement of
TRPV1 in physiological and pathophysiological condi-
tions. Some inflammatory mediators in damaged tissues
including growth factors, neurotransmitters, peptides or
small proteins, lipids, chemokines and cytokines sen-
sitize TRPV1 to its agonists [77]. Even in concentrations
that fail to activate a current, CAPS can sensitize TRPV1
channels to protons and heat. Similarly, protons can
sensitize TRPV1 channels to CAPS and heat [78,79]. The
elevation of temperature or local acidity can in principle
augment the efficacies of partial agonists, transforming
them from weakly or non-pain-producing ligands into nox-
ious chemicals [80,81]. Whereas protons sensitize TRPV1
directly, most of the mediators work through receptor
pathways, which include receptor tyrosine kinases and G-
protein-coupled receptors. It has been reported that phos-
phorylation by protein kinase A (PKA) [82-84] and protein
kinase C (PKC) can sensitize TRPV1 to CAPS, protons or
heat [47,78,85-88]. The phosphorylation of TRPV1 by PKC
acts to potentiate CAPS- or proton-evoked responses and
reduces the temperature threshold for TRPV1 activation.
Others have suggested that isoforms of PKCα [89] or
PKCμ [90] are responsible for the effects described above.
Protein kinase D/PKCμ is a member of the protein kinase
D serine/threonine kinase family that exhibits structural,
enzymological and regulatory features distinct from those
of the PKCs, with which they are related. TRPV1 can also
be phosphorylated by Ca2+ CaM-dependent kinase II
(CaMKII) [91], or Src kinase [92], whilst the phosphatase
calcineurin produces desensitization of the TRPV1 recep-
tor [93]. TRPV1 undergoes two types of desensitization on
activation by CAPS or protons: acute (short-term)
desensitization and tachyphylaxis or loss of sensitivity to
repeated stimulations [14,94]. Physiologically, TRPV1
desensitization can lead to the adaptation of peripheral
neurones to pain perception. The regulatory lipid PIP2 is a
putative intracellular modulator of TRPV1, although there
is some debate as to whether it sensitizes or desensitizes
the channel. Mutations in a C-terminal cytosolic region of
TRPV1 indicate an inhibitory role for PIP2 [95]. However,
others have found that PIP2 sensitizes TRPV1 and that
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portant membrane lipid in terms of TRPV1 activity is chol-
esterol. Cholesterol is a major component of plasma
membranes and is enriched in lipid rafts. It has been
shown to modify the function of many classes of ion chan-
nels [100]. Cholesterol can modify channel activity indir-
ectly by altering physical properties of the surrounding
lipid bilayer, and the highly ordered lipid rafts can serve as
organizing centres for many signalling processes [101].
In recent years compelling evidence has emerged of a
specific interaction between cholesterol and several chan-
nels [100-103]. A supporting role of sphingomyelin and
gangliosides was also demonstrated [104]. Sántha et al.
demonstrated that inhibition of neuronal ganglioside syn-
thesis by inhibition of glucosylceramide synthase reversibly
decreased the CAPS-induced activation and TRPV1 ex-
pression of cultured dorsal root ganglion neurons, appar-
ently leaving other markers of nociceptive neurons, such as
CGRP and IB4, unaffected [105]. Intracellular ATP can also
sensitize TRPV1.
TRPV1 binds and is modulated by Ca2+/CaM, a ubi-
quitous Ca2+ sensor [106,107]. An increase in intracellu-
lar Ca2+ concentration causes TRPV1 desensitization,
and CaM plays a role in mediating this effect [106-108].
CaM interacts in vitro with isolated peptides from the
TRPV1 N-terminal region in a Ca2+-dependent manner
[107], and also binds to the TRPV1 C-terminal region in
a Ca2+-independent manner [106]. The response of
TRPV1 to heat can be modified by tyrosine kinases or
G-protein-coupled receptors. Channel activation can
occur even at normal body temperatures [78,109,110].
Reducing agents such as dithiothreitol (DTT) strongly
increase the thermally induced activity of the TRPV1
channel [111]. Moreover, the oxidizing agents diamide
and chloramine-T also facilitate thermally induced
TRPV1-mediated currents [112]. Alkylating agents, such
as N-ethylmaleimide also strongly and irreversibly affect
heat-evoked responses from TRPV1, lowering the thermal
activation threshold in a DTT-dependent manner [112]. It
follows from these data that TRPV1 is targeted by redox-
active substances that directly modulate the channel activ-
ity, and that channel potentiation may occur under altered
redox states in a tissue, e.g., during ischaemia and/or in-
flammation, presumably leading to hyperalgesia.
Inflammatory agents such as bradykinin, serotonin,
histamine, or prostaglandins can further stimulate TRPV1
activity, either by PKC-dependent pathways [110,113,114],
by releasing the channel from PIP2-dependent inhibition
[99,115], by a PKA-mediated recovery from inactivation
[116,], or by the formation of 12-HPETE [78,117].
Vitally important functions of TRPV1
The role of the TRP channels in pain and neurogenic in-
flammation have been very well covered by previousauthors (e.g. [118-121]) reflecting the enormity of the
role that these channels play in sensory nerve function
at both a central and peripheral level [122]. Thus TRPV1
plays a key role in the development of the burning pain
sensation associated with acute exposure to heat or
CAPS, and with inflammation in peripheral tissues
[28,91]. The receptor seems to play important role in
certain chronic pain conditions, such as neuropathic
pain, osteoarthritis, bone cancer pain, inflammatory
bowel disease and migraine [9,123,124]. Its role in the
central nervous system (CNS) is known to involve pain
processing and modulation, neurogenesis [125] and
thermoregulation [126], amongst others, but is currently
less well understood.
Jancsó and Wollemann [127] have reported that CAPS
stimulates adenylate cyclase activity in the rat cerebral cor-
tex in vitro. Furthermore, direct injection of CAPS into the
preoptic area of the anterior hypothalamus [126] or i.c.v. re-
gion [128] of the rat brain causes hypothermia, suggesting a
role for this channel in thermoregulation. Similarly, sys-
temic administration of TRPV1 antagonists such as
AMG517 [73], AMG0347 [129] and A-425619 [130] causes
an increase in body temperature within approximately 1 h
of treatment [122]. However, antagonist-induced hyperther-
mia may not be mediated by hypothalamic TRPV1 as
peripherally-restricted antagonists still have the capacity to
cause an increase in body temperature [131].
Within the periphery, recent evidence has located
TRPV1 on a variety of non-neuronal tissues (for more
details see Table two in the paper of Fernandes et al.
[122]). Although TRPV1 channel expression has been
shown in a wide variety of tissues, evidence of function-
ality has not yet been demonstrated for all of these.
One of the first cell types in which functionality was
first identified is epidermal keratinocytes. Inoue et al.
[132] demonstrated that both CAPS and acidification
produced elevations in the intracellular calcium concen-
tration in cultured human epidermal keratinocytes that
could be inhibited by the TRPV1 antagonist, CapZ [122].
Similarly, treatment of human skin fibroblasts with
CAPS induced significant changes in the membrane
current and the intracellular calcium level that were an-
tagonized by CapZ [133]. It is therefore clear that TRPV1
is expressed and functional away from sensory nerves.
Physiological or pathophysiological effects of non-
neuronal TRPV1 have been implicated in inflammation,
infection and immunity, the cardiovascular system and
in conditions such as obesity [122].
A physiological/pathophysiological role for non-neuronal
TRPV1 is perhaps nowhere more apparent than in the case
of inflammation, infection and immunity. Although the
effects of these TRPV1 channels are non-neuronal, it is evi-
dent that they may well impact indirectly upon pain and/or
neurogenic inflammation [122]. Keratinocytes functionally
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maintaining the integrity of the immune response in skin
as well as stimulating cutaneous inflammation via pros-
tanoid and cytokine release [134]. TRPV1 activation by
CAPS causes an increase in COX2 expression in human
keratinocytes with a concomitant increase in PGE2 levels
in vitro [135]. An increase in IL-8 is also observed [135]
Stimulation of inflammatory mediator release by TRPV1
agonists from keratinocytes could well have a significant
effect upon sensory nerves that have a high density in
skin [122].
However, there is accumulating evidence that TRPV1
has functional roles away from sensory nerve activity
[122]. As well as keratinocytes, peripheral blood mono-
nuclear cells (PBMCs) are also directly affected by TRPV1
activation. For example, PBMCs undergo apoptosis when
stimulated with CAPS or RTX, an effect that is reversed
by the TRPV1 antagonist, AM630 [136]. There are various
other cells involved in immunity that respond to TRPV1
and TRPA1 activation including bone marrow-derived
dendritic cells, where CAPS leads to dendritic cell matur-
ation and an increase in antigen presentation [137].
TRPV1 is expressed, functional and active within cells
relevant to inflammation, infection and immunity. It is
clear from the studies that TRPV1 at least plays a para-
doxical role in inflammation in vivo, for example, ex-
acerbating inflammation in arthritis and yet in
experimentally induced sepsis, TRPV1 null mice demon-
strate elevated levels of pathological markers in compari-
son with wild type mice [123]. It cannot be ruled out
that this is due to differing effects of neuronal and non-
neuronal TRPV1 channels [122].
TRPV1 have been shown to control vascular responses
either by the well-established neurogenic response that
is mediated by sensory nerves [138] or via a direct effect
on vascular tissue [139,140]. However, the non-neuronal
mechanisms involved in mediating vasodilatation and
oedema formation following TRPV1 activation in vivo
are unclear. TRPV1 on endothelial cells has been shown
to regulate the expression and secretion of endothelial
cell-derived CGRP, which affords protective effects on
endothelial cells [141]. Furthermore, CGRP is a potent
vasodilator [142], and this CGRP may therefore impact
upon blood pressure. Indeed, TRPV1 activation on
sensory nerves also causes CGRP release, leading to a
profound decrease in vascular tone [143]. On the other
hand, TRPV1 expressed on vascular smooth muscle
appears to cause vasoconstriction [140,144,145]. It has
also been suggested that CAPS has biphasic effects on
the vasculature: at lower concentrations, CAPS (up to 10
nM) evokes vasodilation in skin due to sensory nerve ac-
tivation, whereas higher concentrations (0.1–1 mM)
elicit substantial constrictions in skeletal muscle arteri-
oles due to non-neuronal TRPV1 stimulation [140]. Itis unclear whether this difference is due to receptor
sensitivity or a difference in TRPV1 receptor density in
the two tissues. A similar biphasic effect of CAPS has
been demonstrated also in meningeal blood vessels
[146]. TRPV1 may also play a role in vascular responses
during chronic hypoxia where up-regulation of the
TRPV1 gene and protein is observed [147]. Chronic hyp-
oxia has been shown to enhance the ability of human
pulmonary artery smooth muscle cells to proliferate and
to increase resting levels of cytosolic calcium and capacita-
tive calcium entry with both effects being inhibited in a
dose-dependent manner by the TRPV1 antagonist, CapZ
[147]. These results suggest that TRPV1 on smooth
muscle may be a critical pathway or mediator in chronic
hypoxia-induced vascular changes [122].
Obesity is one of the most significant health issues in
western society due to the morbidity associated with this
condition that is increasing in prevalence. Obesity is in-
duced by the hypertrophy of adipocytes and the recruit-
ment of new adipocytes from precursor cells. These
processes are dependent on the regulation of adipocyte
differentiation. CAPS has been shown to inhibit adipocyte
differentiation in vitro by activation of AMP-activated pro-
tein kinase [148]. Furthermore, Hsu and Yen [149] have
shown that treatment of preadipocytes with CAPS de-
creases the number of normal adipocytes and increases
the number of early apoptotic and late apoptotic cells in a
dose-dependent manner. Thus the overall effect of TRPV1
modulation in obesity is stark. Both animal [150] and hu-
man [151] data have indicated that the consumption of
CAPS- or non-pungent capsiate-containing foods is corre-
lated with a reduced incidence of obesity. Similarly, oral
administration of CAPS alone also suppresses body fat ac-
cumulation in mice [151], and dietary CAPS can reduce
obesity-induced insulin resistance and hepatic steatosis in
mice fed a high fat diet [122,152].
In recent years, a role for TRPV1 in thermoregulation
has also been identified which may, at least in part, be due
to changes in thermogenesis (for review, see [72,153,154]).
For many years, CAPS has been known to cause a cen-
trally mediated hypothermia in mice [126]. In contrast, its
intragastric administration enhances thermogenesis and
heat diffusion [155]. Similarly, the jejunal administration
of non-pungent CAPS analogues was shown to increase
energy expenditure via direct activation of TRPV1 located
on intestinal extrinsic nerves [156]. Interestingly, some
TRPV1 antagonists cause hyperthermia, associated with in-
creased thermogenesis [130] through a peripheral mechan-
ism [131], whilst TRPV1 gene knock down does not affect
body temperature in mice [157] and TRPV1 knockout
mice exhibit a normal basal body temperature [122,129].
TRPV1 in the alimentary tract has also been impli-
cated in metabolism, hair growth regulation [158], and
the development of cancer [159].
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have the potential to provide exciting opportunities for
therapeutic interventions. Its known functions in both
health and disease have been continuously expanding
promoting a better understanding of TRPV1.
TRPV1 expression
TRPV1 channels are mainly expressed on primary sen-
sory neurones. They have been detected in key areas of
the pain transduction pathway: on terminals of small- to
medium-diameter nociceptors, such as peptidergic and
non-peptidergic C fibres, some Aδ fibres [28,79]; in skin
nerve endings, DRGs, nodose ganglia, trigeminal ganglia
of the peripheral nervous system, as well as laminae I
and II [79] of the dorsal horn of the spinal chord. Projec-
tions may also extend into laminae V and X [79]. More-
over TRPV1 has been found in different brain regions,
such as in dopaminergic neurones of the substantia nigra,
hippocampal pyramidal neurones, hypothalamic neurones,
neurones in the locus coeruleus, and in various layers of
the cortex [25,160,161]. The channel is present to a lesser
extent in the hippocampus, cortex, olfactory bulb and
cerebellum in the CNS [44,162]. However, more recently,
the use of TRPV1 reporter mice has revolutionized the
study of TRPV1 expression, and they would suggest that
the expression of this receptor is minimal within a few
discrete brain regions, most obviously in the vicinity of
the caudal hypothalamus [122,145].
TRPV1 is additionally expressed in discrete spots in the
plasma membrane and cytosol of different non-neuronal
cells such as the endothelium, immune cells (lymphocytes,
dendritic cells and mast cells), keratinocytes, smooth
muscle cells and urothelium, thymocytes and macro-
phages, some of which are known to be involved in
inflammation [159]. An increased level of TRPV1 expres-
sion has been demonstrated in the sensory fibres of
patients with an inflamed oesophagus (gastro-oesophageal
reflex disease) or an inflamed bowel (both ulcerative col-
itis and Crohn’s disease), or with chronic breast tender-
ness and pain [163]. There is likewise an increased TRPV1
expression in the sensory fibres of patients with rectal
hypersensitivity and faecal urgency, and this increase is
directly correlated with the degree of thermal and mech-
anical sensitivity [164].
Functionally important amino acid sites and their
mutations in the TRPV1
Emerging data of TRP channel research has elucidated
roles for TRP channels in diverse therapeutic areas, and
resulted in the identification of numerous potential drug
targets beyond TRPV1. Success in finding a viable ther-
apy targeting the TRPV1 channel depends on experi-
mental studies aimed at obtaining detailed knowledge of
the channel protein. TRPV1 pharmacology has reliedheavily upon information derived from studies of site-
directed mutants of the recombinant channel(s) by the
identification of the most appropriate acting sites for
potential drug candidates. Figure 1 indicates the mu-
tated residues and the functional changes evoked by
them, and also depicts the most important structural
properties of TRPV1 (For high resolution figure, see
Additional file 1). In order the easier comprehensibility
and the more effective usability of the data, a compre-
hensive table summarizes the information of the mu-
tants at the end of the article (see Table 1).
Mutations affecting agonist action and/or binding
CAPS and RTX
Jordt et al. provided molecular evidence that the muta-
tion of E600 caused enhanced sensitivity to CAPS [43].
In the experiments by Jordt et al., replacement of Glu by
Gln (E600Q) produced a greater than 10-fold leftward
shift in the CAPS dose–response curve, with EC50 values
of 520 and 40 nM for wild type and mutant receptors,
respectively (Figure 1). Moreover, channels bearing a Lys
at this position (E600K) exhibited even higher agonist
sensitivity, showing saturated current responses at 50
nM CAPS. Introduction of neutral or positive residues
at the E600 site potentiates responses to CAPS, whereas
introduction of a residue with lower pKa (E600D) de-
creases the channel sensitivity to this stimulus [43].
Welch et al. identified E636, D646 and E648 as specific
contributors to the CAPS response without affecting the
proton or thermal sensitivity. E636Q, D646N and E648Q
had a threefold greater sensitivity to CAPS than the wild
type TRPV1 channels [165].
A triple mutant (N676F/M677A/L678P) was reported
by Kuzhikandathil et al. to disrupt the ability of CAPS
and RTX to activate TRPV1, while retaining the ability
to respond to protons [166], suggesting that distinct
amino acids that are close to or in TM6 control the gat-
ing in response to several modes of TRPV1 activation.
Deletion of R114 and E761 in the N- and C-termini
can block CAPS-induced currents without affecting
TRPV1 activation by heat [16].
F489Y resulted in a rightward shift of the CAPS con-
centration of half-maximal activation (EC50) [167]. Jordt
et al. [168] conducted a search for residues involved in
the action of CAPS on the basis of the differences be-
tween avian TRPV1 and mammalian (rat and human)
orthologues [169], and found eight amino acids in the
vicinity of TM3 that differ between the two forms, which
may account for the species-specific sensitivity to CAPS
(F507, Q519, F522, M523, S532, K535, E536 and
T550 residues of rTRPV1 corresponding to I515, N527,
L530, L531, C540, E543, L544 and A558 of chicken
TRPV1, respectively). Exchange of any one of the Q519,
F522, M523, S532, K535 or E536 residues for the
Figure 1 (See legend on next page.)
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Figure 1 Summary of the mutated sites of rTRPV1 The figure summarizes the effect of 112 unique mutated sites along the rTRPV1 on
the function of the channel. Coloured circles indicate the involvement of the given residue in the corresponding process. Coloured boxes show
the putative location of some structural elements on the rTRPV1 sequence. Sequence and region information: TRPV1_RAT (O35433) (www.uniprot.org).
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sufficinet to ablate the vanilloid sensitivity of rTRPV1.
They investigated the TM2-4 regions for sites involved
in CAPS, RTX or proton action and observed that sub-
stitutions at two positions (R491G in TM2 and S512F
in TM3) led to dramatic reductions in both proton- and
CAPS-evoked currents. However, the introduction of
other mutations at these positions (S512A, S512T or
R491E) resulted in a greater preservation of functional-
ity, and in each case a greater reduction in CAPS sensi-
tivity was observed compared to extracellular protons.
The mutant S512Y displayed little response to CAPS up
to 100 μM, and no detectable specific binding of RTX.
Nevertheless, the proton sensitivity was retained, as were
the responses to noxious heat, albeit with a slightly
higher thermal threshold (>48°C) and smaller maximal
amplitudes compared to wild type receptors. An ex-
tended mutational analysis of the conserved residues ad-
jacent to S512 (D509, S510, Y511, E513 and I514)
revealed the most significant effects with the mutant
Y511A. Despite lacking any significant CAPS sensitivity,
this channel exhibited normal heat- and proton-evoked re-
sponses, with a thermal threshold and current amplitudes
that were indistinguishable from those of the wild type re-
ceptor. In tests of whether the aromatic nature of the
residue at position 511 is essential for ligand binding,
substitution with a Phe (Y511F) was found to have only
moderate effects, whereas substitution with a non-aromatic
Cys (Y511C) again eliminated the CAPS sensitivity [168].
Jung et al. [16] identified two regions near Arg114 and
Glu761 in the cytosolic tails of TRPV1 that determine
ligand binding. Because the Arg114 and Glu761 resi-
dues are charged, it is likely that these charges are ne-
cessary for vanilloid binding. When positively charged
Arg114 was replaced by a neutral amino acid, Ala, the
mutant (R114A) elicited a CAPS-induced current com-
parable with that of the wild type TRPV1. However,
when the Arg at 114 was replaced by negatively charged
glutamate (R114E), a significant reduction in CAPS-
induced current was observed with no apparent specific
[3H]RTX binding. Because the adjacent amino acid,
R115 is also positively charged, it was also replaced with
Asp (R115D). The R115D mutant also abolished the
CAPS-sensitive currents, indicating that charge at Arg-
115 contributes equally to activation by CAPS. When
the negatively charged Glu at 761 was changed to Gln, a
neutral amino acid retaining a similar structure, the mu-
tant (E761Q) elicited a great reduction in Icap (~98.0%
reduction), and had no specific binding for [3H]RTX.Furthermore, when the Glu at 761 was substituted with
positively charged Lys, the mutant (E761K) showed no
current response to CAPS or ability to bind [3H]RTX.
R114E and E761K elicited current responses to heat,
but not to acid (pH 5.5).
These results reflect the necessity of the negative
charge of Glu at 761 for ligand recognition and the fact
that the positive charge at R114 determines the ligand
binding to the channel, but to a lesser extent than the
charge at E761 [16].
Chou et al. [170] showed the residue in position 547
to be a key contributor to RTX binding of TRPV1 by ex-
changing a single amino acid between the human and
rat counterpart. Systematic replacement of the amino
acids in the TM1 to TM4 domain of hTRPV1 with the
corresponding rTRPV1 residues identified a single con-
servative substitution of Met for Leu (M547L) at pos-
ition 547 that accounted for the species difference in
RTX binding. The amino acid at this position also af-
fected the potency of the antagonists I-RTX and
capsazepine for inhibiting [3H]RTX binding and the
agonist response to RTX. The M547A mutation in
rTRPV1 reduced RTX affinity to the same degree as
M547L (≈30-fold). A more radical mutation, M547Q,
decreased potency to a smaller degree than either
M547A or M547L. In the case of L547A and L547Q
mutations in the hTRPV1 no [3H]RTX binding and little
channel activity were detected even though protein was
seen on western blots. The human L547M mutation has
a higher affinity for RTX than wild type rTRPV1, and
similarly the rat M547L displayed a lower affinity than
wild type hTRPV1 [170]. M547, W549 and T550 in the
S4 segment participate in ligand interactions [171,172].
F489 proved to take part in the CAPS activation of the
channel [167], probably because of its close proximity to
a domain containing mutations R491, Y511, and S512
shown to be implicated in CAPS sensitivity [168,173].
When associated with T704I, S502A was found to lose
the ability to be activated by CAPS and lose the ability
of vanilloid binding [85,91,174].
Rabbit oTRPV1 can be activated by heat (45°C) and pro-
tons (pH 5), but it is 100-fold less sensitive to vanilloid acti-
vation than hTRPV1 or rTRPV1, and oTRPV1-transfected
HEK293 cells did not exhibit any specific [3H]RTX binding.
Gavva et al. [171] constructed a rat-rabbit chimera of
TRPV1 by the transfer of TM3 through 4 (S505-T550)
from rTRPV1 to oTRPV1. The chimera displayed enhanced
sensitivity to vanilloids, similarly to rTRPV1. Additionally, a
human-rabbit chimera was created by transferring the
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lysis again showed that this chimera also gained sensitivity
to CAPS, further confirming that the TM3-4 region is
responsible for vanilloid sensitivity.
On the basis of the 10 differences found between
rTRPV1 and oTRPV1 and the six between hTRPV1 and
oTRPV1, Gavva et al. mutated the residues that in rabbit
differ from those in both rTRPV1 and hTRPV1 (A505S,
A520S, C534R, T540S and I550T). Changing the single
residue at 550 in rabbit to the corresponding residue
found in rTRPV1 and hTRPV1 (I550T) was sufficient to
confer a gain of function for activation by CAPS.
Changing the residues A505S, A520S, C534R and T540S
individually or in various combinations did not cause
any changes in the responses of oTRPV1 to vanilloids.
For a better understanding of the biophysical require-
ments at position 550, Gavva et al. explored several
polar and hydrophobic substitutions. A gain in CAPS
sensitivity was observed when Ser was introduced in-
stead of Thr (I550S), the small non-polar Ala (I550A)
resulted in only a partial gain of CAPS sensitivity, while
thiol group containing-residue Cys (I550C) resulted in a
very small gain in oTRPV1 CAPS sensitivity. Introduc-
tion of Tyr (I550Y) with its bulky phenolic side-chain at
this position resulted in a complete loss of TRPV1 re-
sponse to vanilloid, proton or heat activation, although
the expression level of this mutant remained comparable
to the others. To verify further that the T550 found in
native rTRPV1 hTRPV1 contributes to the vanilloid
sensitivity of TRPV1, the effects of substitution of the
natural Thr by the oTRPV1 Ile 550 (T550Y) residue
were examined. 45Ca2+-uptake experiments revealed a
10-fold loss in sensitivity to CAPS of rTRPV1-T550I,
and a 40-fold loss in sensitivity of hTRPV1-T550I.
Gavva et al. [171] confirmed the finding of Jordt and
Julius that T511 is critical for vanilloid sensitivity. Both
rTRPV1-Y511A and hTRPV1-Y511A had lower vanilloid
sensitivity. They tested the CAPS sensitivity of the
oTRPV1 double mutant containing I550T (gain of func-
tion) and Y511A (loss of function), i.e., oTRPV1-Y511A/
I550T. Compared with oTRPV1-I550T, the reduction in
CAPS sensitivity of oTRPV1-Y511A/I550T in the 45Ca2+
uptake assay was >100-fold. In fact, the magnitude of the
loss in CAPS sensitivity by Y511A was greater than the
gain seen in I550T. The T550I mutation resulted in the
CAPS dose-response curve shifting 10-fold to the right,
relative to the control, without reducing RTX sensitivity in
the 45Ca2+ uptake assay. However, [3H]RTX specific
binding was significantly reduced in rTRPV1-T550I-
transfected cells. A series of single point mutations were
introduced into oTRPV1 (M514I, A525V, T526S,
H533Q and L547M) to mimic the residues in rTRPV1,
which has been shown to display the highest RTX-binding
affinity. Replacement of the oTRPV1 residues at M514I,A525V, T526S and H533Q individually did not alter the
oTRPV1 response to CAPS or RTX. The single residue
change L547M in oTRPV1 resulted in a selective gain of
~30-fold higher sensitivity to RTX with no apparent
change in CAPS sensitivity in 45Ca2+-uptake assays.
oTRPV1-L547M demonstrated greater sensitivity to RTX,
but failed to show any measurable [3H]RTX binding, and
it was therefore hypothesized that L547M contributes to
RTX sensitivity, but requires additional residues such as
T550 to attain the affinity needed for measurable [3H]
RTX binding above the assay background. A reverse mu-
tation in rTRPV1 (M547L) displayed similar responses to
CAPS and RTX in the functional 45Ca2+-uptake assay. To
test whether oTRPV1 might require bothT550 andM547
to attain measurable [3H]RTX binding, the oTRPV1
L547M/I550T double mutant was constructed and its
vanilloid sensitivity was examined in functional 45Ca2+-up-
take and [3H]RTX binding assays. As predicted, oTRPV1-
L547M/I550T exhibited strong [3H]RTX binding together
with only a slight increase in functional sensitivity to
CAPS and a somewhat greater increase for RTX. This
demonstrates that Met547 and Thr550, as present in na-
tive rTRPV1, are required for measurable [3H]RTX bind-
ing in oTRPV1. oTRPV1-I550T and L547M/I550T
resulted in slight changes in sensitivity to pH 5.5. Gavva
et al. hypothesized that Y511, M547 and T550 may be
present in the binding pocket and are important molecu-
lar determinants for vanilloid sensitivity [171].
Johnson et al. [173] investigated the role of two resi-
dues (S512 and M547) identified earlier to be respon-
sible for major species-specific differences in vanilloid
activity in the response of the channel to a variety of li-
gands. Their initial studies confirmed the clear species-
specific differences in RTX potency described previously
by Chou et al. [170]. RTX activated wild type rTRPV1
with a fourfold higher potency than the wild type
hTRPV1. Johnson et al. switched the residues at position
547 between the two receptor homologs creating the
M547L rat mutant and the L547M human one. L547M
produced a significantly more RTX-sensitive channel with
the EC50 value comparable with that of the wild type rat
receptor. Conversely, when the reverse mutation was
made in the rat construct (M547L) a loss of function was
observed, although, the change was not significant.
The species-specific differences in CAPS sensitivity
were also investigated. CAPS was found to be signifi-
cantly more potent at the wild type hTRPV1 than at the
wild type rTRPV1 channel. When the 547 residue was
switched between the rat and the human constructs, the
sensitivity to the agonist was again altered. In this in-
stance, this mutation caused a significant decrease in po-
tency in the human mutant (L547M) compared with the
human wild type, with an EC50 value comparable with
that of the wild type rTRPV1. As for RTX, when the
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there was no significant difference [173].
Susankova et al. [175] Ala-scanned the residues Y666-
G683 containing the most conserved region of the TRP
protein family.
Three mutant channels (Y666A, I672A, N676A) showed
no CAPS-evoked activity at all. These mutants were also
pH insensitive, they were not activated in the absence of
extracellular Ca2+, and they gave very small and nonspecific
heat-induced membrane currents. Y666A and N676A
possessing no any potentiated currents in response to 47°C
and 30 μM CAPS applied together, proved to be non-
functional mutants, suggesting that these two residues
within the inner-pore region of rTRPV1 are critical for
channel functionality.
Co-application CAPS (30 μM) and heat stimuli (43°C)
caused efficient potentiation in mutants I672A, L673A,
L674A, L678A, and M682A which were functionally si-
lent or only barely responded to CAPS at base
temperature. Compared with wild type TRPV1 however,
the current densities of the CAPS-induced responses
measured at 47°C were significantly reduced in: I668A,
I672A, L673A, L674A, L675A, and M682A. These
mutations but L675, whose heat-activation was un-
affected, caused also significantly impaired heat- and
CAPS-activation.
Y671A dramatically lowered the CAPS EC50 value in
the experiments of Mohapatra et al. [176].
Susankova et al. [175] further studied this mutant and
reported that responses to CAPS were not potentiated
by heat, but in contrast to the other mutants and the
wild type channel, CAPS-evoked responses were consist-
ently inhibited by heating above 30°C. Susankova et al.
reasoned that the loss of potentiation in Y671A might
be attributable to changes in agonist sensitivity. When
the channels were desensitized by repeated applications
of CAPS (1μM and/or 30μM), the heat-induced potenti-
ation reappeared. Y761 might contribute to allosteric
coupling between temperature- and CAPS- dependent
activation mechanisms.
Susankova et al. evaluated the changes in CAPS re-
sponsiveness evoked by Ala mutations by comparing
their relative sensitivities at 1 and 30 μM CAPS at 47°C.
An alternating pattern was found with unaltered sensi-
tivity to CAPS in T670A, L675A, G683A, and wild type
channels and a reduced but not abolished CAPS sensi-
tivity in mutations I668A, Y671A, I672A, L673A,
L678A, and M682A. Interestingly, the mutation of Leu
673 to Ile (L673I) in the experiments of Myers et al.
[177] however caused a channel with elevated basal ac-
tivity and significant cytotoxicity.
To further assess the maximal CAPS-induced re-
sponses in the mutants, Susankova et al. compared the
inward currents measured at 47°C in the absence andpresence of a high concentration of CAPS. Except for
Y666A, N676A, and I679A, the inward currents were
significantly greater in the presence of 30 μM CAPS
than in its absence. The lack of mutual potentiation be-
tween the two stimuli in the former two mutants was
caused by their insensitivity to CAPS. Notably, the muta-
tion I679A retained normal sensitivities to both stimuli,
although it completely removed their mutual potenti-
ation at 47°C. In several residues (V667A, T670A,
I672A, L673A and L675A), the degree of the CAPS-
induced increase in the amplitude of the inward current
at 47°C was clearly reduced, although these changes did
not achieve statistical significance.
Changes induced by individual mutations in the 1 μM
versus 30 μM CAPS-induced current relationships mea-
sured at 47°C might reflect the changes either in CAPS
sensitivity or in the allosteric linkage between CAPS and
heat sensor movements and channel opening. Specific-
ally, mutation I679A appeared to cause a decrease in
the synergistic interaction of CAPS and heat with the
TRPV1 channel.
Susankova et al. denoted that the periodicity observed
in the relationships between the maximal activation cap-
acities obtained for 1 and 30 μM CAPS at 47°C supports
the hypothesis that there exists a structural explanation
for the gating of the TRPV1 channel by chemical stimuli.
The pattern of sensitivity to CAPS (every three to four
substitutions) is consistent with an α-helical structure
contributing to CAPS-induced channel gating. Similar
pattern of residues involved in the CAPS sensitivity can
be observed in TM3 and TM3-TM4 linker region identi-
fied by Jordt and Julius [168]. The repetitive patterns of
CAPS sensitive residues apparent in both papers how-
ever seem to fit better for a 3.4 residues per turn of the
helix than for a 3.6 one. This may further support the
finding of Salazar et al. [178] who reported that the TM6
of TRPV1 represent amphipathic helix with 3.4 residues
per turn and a P(φ) value of 107° rather than α-helix
with 3.6 residues per turn and a P(φ) value of 100°. Con-
sidering the above mentioned findings, all the TM heli-
ces of TRPV1 might be regarded to have the same
structure [175].
Boukalova et al. [179] found that the E570Q mutation
accelerated the rate of activation of the channel. In con-
trast, a significantly lower rate of activation was ob-
served in mutated rTRPV1 channels containing
mutations R557A, M581T, D576R, Q560H, R557K and
E570R, indicating contribution of the transduction of
the CAPS-binding signal to the opening of the pore. The
estimated deactivation time (the time taken for the
current to decrease to 50% of its level before removal of
the CAPS) was markedly longer in R557K as compared
with the wild type, but not in R557A or R557L, indicat-
ing that the specific side-chain properties of R557, and
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for the deactivation gating process. In R557A, R557K,
Q560H and M581T, the second response to 1 μM CAPS
reapplied after an apparent wash-out had a faster onset
than in the wild type, suggesting an incomplete deactiva-
tion process. The time courses of the CAPS-induced
whole-cell currents through R557A, R557L, E570R,
D576R, R579A and R576R/R579D closely resembled
those of wild type TRPV1. In contrast, R557E/E570R
exhibited slower activation and deactivation kinetics. A
significantly faster offset of CAPS-dependent responses
was detected in E570A and R576R/R579E. The muta-
tions causing similar defects in the voltage-dependence
affected the chemical sensitivity of TRPV1 very differ-
ently [179].
Mutation studies by Lee et al. [180] and other groups,
along with comparisons of TRPV1 variants from species
sensitive or insensitive to vanilloids, have identified im-
portant residues for ligand binding, such as Tyr511,
Met547 and Thr550 [168,170,171].
Lee et al. [180] generated a series of rTRPV1 mutants
within the TM3 (Y511A, Y511F) and TM4 (M547L,
T550A, T550I, T550S) regions, and performed docking
studies with the prototypical agonists, CAPS and RTX,
to assess their roles in ligand recognition. Their muta-
tional studies based on the foregoing in silico docking
experiments resulted in the discovery that the vanillyl
moiety of CAPS oriented towards Y511, while the tail
end extended towards M547. The vanillyl moiety formed
π-π stacking and hydrophobic interactions with Y511,
and H-bonding with S512. Moreover, the carbonyl
group participated in H-bonding interactions with Y511
and L571. Mutation of Tyr in position 511 to Phe
(Y511F) had only a slight effect on the activity of CAPS,
but its mutation to Ala (Y511A) caused loss of the π-π
stacking and H-bonding capabilities, leading to a sharp
decrease in CAPS activity. The mutation of T550I also
evoked a significant decrease in CAPS activity, but the
influence of the change of Thr to Ala (T550A) or Ser
(T550S) was much weaker. This may reflect the bulky
side-chain of Ile disturbing the binding of the nonenyl
tail of CAPS. Although the hydrophobic nonenyl tail
was oriented towards the upper hydrophobic region of
the binding site, it did not fully occupy the hydrophobic
region of the two shallow hydrophobic areas composed
of F543 and M547 because it is linear and too short to
reach both areas. These data indicate the relevance of
the overall size, shape and/or hydrophobicity of the lipo-
philic side chain region for binding.
In the case of RTX, the vanillyl moiety appeared to
form π-π stacking with Y511, as did that of CAPS. The
importance of Y511 in RTX binding was also confirmed
by their mutation study. When Tyr 511 was mutated to
Phe (Y511F), the binding affinity of RTX decreased lessthan fourfold, as the π-π stacking and hydrophobic in-
teractions of the vanillyl group of RTX were maintained.
As compared with the relatively short and linear tail of
CAPS, the C13-propenyl group of RTX contributed to
the hydrophobic interaction with M547, and its import-
ance in RTX binding was also justified by the mutation
studies. When Met was mutated to Ile (M547I), the
binding affinity of RTX decreased more than 11-fold.
This may be caused by the greater ability of M547 than
of Leu to extend to make the hydrophobic interaction
with RTX. In addition, the C4-OH group of RTX
seemed to fit well with the small side-chain of T550 in
addition to H-bonding with the residue. This docking re-
sult is in agreement with the mutation data that neither
mutated T550S nor T550A caused any binding loss
relative to the wild type, while T550I led to a drastic de-
crease (over 20-fold) in RTX-binding affinity. As with
CAPS binding, the bulky side-chain of Ile could cause
steric interference with the binding of RTX. It was no-
ticeable that the orthophenyl group of RTX underwent
hydrophobic interaction with L515. The ultrapotency of
RTX might be due to the fact that it could occupy the
binding site fully, taking maximum advantage of the
multiple possible binding interactions with TRPV1.
Since RTX has phenyl rings in both the 4-hydroxy-3-
methoxyphenyl and lipophilic side chain regions and
there are hydrophobic residues at both ends of the binding
site, RTX could flip over and achieve a minor binding
mode. In this case, the vanillyl moiety would point towards
M547 and participate in the hydrophobic interaction. Cor-
respondingly, the orthophenyl group would orient towards
Y511. The C20-ester seemed to take part in H-bonding in-
teractions with N551 and the C13-propenyl group formed
the hydrophobic interaction with L515 [180].APB
Boukalova et al. [179] reported that the inward currents
induced by 300 μM 2-APB were reduced in R557L,
R557K, Q560H, E570Q and E570R and most strongly
(>50-fold) in K571E, which was normal in all other as-
pects of TRPV1 activation (Figure 1).Allicin
The TRPA1 channel, which is co-expressed in many of
the same neurones as TRPV1, has been proposed to be
the sole target for the actions of allicin [56,181,182].
However, other groups have reported that TRPV1 is also
a target for the actions of this compound [57,183-185].
The agonist action of allicin was confirmed by Salazar
et al. [186], who further demonstrated that the allicin be-
haves as a TRPV1 agonist through the covalent modifi-
cation of a single Cys localized in the N-terminus of the
channel at position C157 [187] (Figure 1).
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The heat activation pathway is largely unknown, al-
though the outer pore region, including the turret and
the selectivity filter-to-S6 linker, is clearly part of the
protein structure participating in the heat-induced
conformational rearrangement. Intensive studies of
thermo TRP channels have so far indicated numerous
channel regions that contribute to temperature-
dependent activation. Exchanging the intracellular C-
termini between TRPV1 and the cold-activated
TRPM8 channel was found to switch their sensitivity
to heat [188]. This result is consistent with the earlier
observation that deletion of the last 72 amino acids of
the TRPV1 C-terminus influenced channel activation
(though in a modality-independent manner) [84]. Fur-
thermore, the intracellular segment between ANK and
TM1 was recently proposed to serve as the thermal
sensor for TRPV1 [189,190].
Introduction of neutral or positive residues at the
E600 site (E600Q and E600K) potentiated the responses
to heat, whereas the introduction of a residue with lower
pKa (E600D) decreased the channel sensitivity to it [43]
(Figure 1).
Susankova et al. [175] performed Ala-scanning of the
residues Y666-G683. The mutations I668A, L669A,
Y671A, I672A, L673A, L674A, M677A, L678A and
M682A blunted the heat-induced current responses. To
obtain a more complete picture of how the individual
mutations affect the heat sensitivity of the TRPV1 chan-
nel and to further characterize the specificity of their
temperature-induced responses, the temperature thresh-
old for activation and the temperature coefficient (Q10)
from the Arrhenius plots of individual current–temperature
relationships were quantified.
The most frequently observed phenotype was a left-
ward shift in the temperature threshold (V667A, I668A,
L669A, L673A, L674A, M677A, L678A and M682A).
Seven mutations (T670A, Y671A, I672A, L675A,
I679A, L681A and G683A) had thermal thresholds no
different from wild type TRPV1. Except for the T670A,
L681A, and G683A, the mutations strongly reduced Q10
in all mutants tested.
Susankova et al. claimed that average temperature-
dependent activation profile with the five peaks sepa-
rated by four troughs at residues I672-L674, N676,
L678, and M682 might correspond an α-helical struc-
ture, which most likely represents the inner-pore region
of the TRPV1 channel. The results of Susankova et al.
also provide functional support for the role of the puta-
tive inner-pore region in controlling the gating of the
vanilloid receptor TRPV1 channel.
L669A and M677A are significantly less sensitive to
heat without a significant change of CAPS- or heat-
potentiated CAPS currents suggesting that theseresidues are involved in heat activation of the channel,
but not in potentiation by heat. L678A displayed a re-
duced sensitivity to heat and CAPS with an unaffected
heat-potentiated current, suggesting a role of L678 in
the process of CAPS- and heat- activation, but not in
the potentiation mechanism. This finding somewhat
contradicts to the results of Kuzhikandathil et al.
[166] who demonstrated M677 to affect the ability of
CAPS and RTX to activate TRPV1 without changing
the channel's response to protons however working on
a triple mutant (N676F/M677A/L678P) containing
channel [175].
By generating a chimera between the TRPV1 and
TRPM8 channels, in which the region V686 to W752 of
TRPV1 was replaced by the same C-terminal region of
TRPM8 (V982 to W1055), Brauchi et al. [191] identified
TRPV1 C-terminal amino acids Q727 and W752 as be-
ing the minimum portion able to turn TRPM8 into a
heat receptor.
The mutations N628K, N652T and Y653T resulted
in TRPV1 channels responding normally to CAPS
and pH, but whose heat responses were reduced in
amplitude and shifted to higher temperatures. More-
over, the time course of activation of these single
point mutants was identical or very similar as com-
pared with wild type TRPV1, suggesting that the
desensitization was not strongly altered [167]. A
double mutant N652T/Y653T and a triple mutant
N628K/N652T/Y653T yielded receptors with CAPS,
2APB and pH EC50 values and maximal responses
that were indistinguishable from that of wild type
TRPV1, but with a further reduction in temperature
responses [167]. The triple mutant (N628K/N652T/
Y653T) exhibited altered heat-gating kinetics. Whilst
the unitary conductance of the wild type TRPV1 and
the triple mutant channel was identical, the triple
mutant possessed channel openings of only short (<1 ms)
durations, and the longer (~10 ms) ones proved to be
completely absent. The triple mutant, however, is nor-
mally gated by CAPS [167].
The T633A mutant exhibited a weaker response to
heat, reaching ~32% of the 1 μM CAPS current. In con-
trast with the change in peak activity, however, the ther-
mal activation threshold coincided with that of the wild
type (~42°C) [192]. A less severe perturbation to the tur-
ret region of the TRPV1 channel by deletion of its first
10 amino acids (ΔG603-S612) substantially and specific-
ally affected the heat activation but not CAPS activation
of the channel [190].
A significantly higher threshold for heat activation was
detected by Boukalova et al. [179] for E570A. The
Y554F, Y555F, Q561H, E570Q, E570R, K571E, R575A
and R579D mutations left the threshold for heat activa-
tion unchanged.
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Jordt et al. [43] demonstrated that E600 serves as a fun-
damental regulatory site for the proton potentiation of
vanilloid receptor activity over a physiologically relevant
range (pH 6–8), but not in proton or heat activation.
The E600Q mutants retained the ability to be activated
by acidic conditions or heat, but differed from the wild
type receptor in two significant ways (Figure 1). First,
upon heat activation the initial heat stimulus produced a
relatively large peak current response that was much
closer to the final plateau value than that typically ob-
served with wild type channels. Second, bath acidifica-
tion failed to potentiate peak currents beyond this
steady-state value. Similar results were obtained with oo-
cytes expressing the E600A and E600S mutants. The
pH dependence of thermal activation was related to the
side-chain charge of the residue at position 600: heat-
evoked currents in the E600D mutant were potentiated
only when the bath pH dropped below 6.5. The E600H
mutants, on the other hand, showed continuous potenti-
ation over the entire pH range tested (9.0 to 5.0), but
the extent of potentiation was significantly less than that
observed for wild type or E600D channels. For E600Q
or other mutants having non-titratable amino acids at
this position, the magnitude of the heat-evoked currents
was largely independent of the extracellular pH. The
D601N and E648Q mutants exhibited a phenotype
characterized by reduced proton-evoked responses, with
normal CAPS sensitivity. The E648A mutants demon-
strated an even greater decrease in proton-activated
current amplitudes, whereas the CAPS- or heat-evoked
currents did not differ significantly from those of wild
type or E648Q channels [43]. This finding is in direct
contradiction to the one made by Welch et al., who
identified E648 as specific contributor to the CAPS re-
sponse without affecting the proton or thermal sensitiv-
ity [165]. E458Q, D471N, E478Q, E536Q, H614Q,
E636Q, D646N, E651Q and D654N mutations were
also tested by Jordt et al. [43], but no phenotype was
reported in terms of acid activation or potentiation.)
E600V caused the complete and specific loss of pH sen-
sitivity [167].
Deletion of R114 was found by Jung et al. [16] to
abolish the sensitivity to acid. When the positively
charged Arg at 114 was replaced by a neutral amino
acid, Ala, the mutant (R114A) elicited an Icap compar-
able with that of the wild type TRPV1. However, when
the Arg at 114 was replaced by negatively charged Glu
(R114E), a significant reduction (~97% reduction) in
Icap was observed with no apparent specific [
3H]RTX
binding.
Sutton et al. reported that the S512Y mutant caused a
small but significant decrease in the ability of protons to
gate the TRPV1 channel [193].A mutation of hTRPV1-L547M by Johnson et al. [173]
caused a decrease in the potency of protons, but no in-
crease was seen when the reverse switch was made in
the rat receptor (M547L).
E651 was found to be important for pH activation [192].
Substitution of the residue T633 by Ala abrogated low
pH-activated currents, but the T633A mutant exhibited
normal CAPS responses, including rapid activation kinet-
ics and large steady-state currents. Furthermore, the po-
tentiation by low pH was also retained, despite the loss of
the low pH sensitivity for direct activation. Conserved resi-
dues on the N-terminal end of the pore helix were also
mutated by Ryu et al., i.e., Y627A and S629A. Both mu-
tants were functional and produced relatively normal re-
sponses to CAPS when applied either alone or in
combination with mildly acidic pH. The mutants were also
activated by low pH directly, albeit with a slightly smaller
maximal current than their wild type counterparts. The
data suggest that these residues may contribute to, but do
not play a pivotal role in the proton activation of TRPV1
as T633 does [192]. In the wild type counterpart, pH 5.5
evoked long bursts of activity, in which the openings were
separated by brief closures. The T633A mutant instead
showed rare spike-like openings. The mutation drastically
slowed the opening rate at low pH. The significant short-
ening of the open time suggests that the mutation destabi-
lizes the open conformation of the channel. T633 was
systematically mutated to others, including Y, R, Q, N, L,
K, E, D, V, S and A, which span both polarity and size.
Substitutions with polar residues such as Q, N and Y or
the charged residues R, K, E and D all resulted in non-
functional channels. The T633S mutation was functional,
but with a significant reduction in low pH current and a
slow activation by CAPS. However, the T633V mutation
preserved the wild type responses in all aspects. On substi-
tution with Leu, containing a larger hydrophobic side-
chain, the channel became non-functional. Together, these
results suggested that T633 is involved in functional inter-
actions in a compact hydrophobic environment. The size
of the side-chain at this position is crucial. Replacing Thr
by Ala, a smaller side-chain, was able to preserve the
CAPS response while abrogating the low pH activation; a
larger side-chain substitution at this position, on the other
hand, became deleterious [192]. The K535E, E536W,
V538L and A539P residues were clustered around the
centre of the loop, and the mutations appeared to impact
predominantly the proton responses. V538L resulted in
no detectable current at pH 5.5, while retaining >93% of
the wild type peak CAPS response. The CAPS response of
E536W was also reduced; however, this mutation, as with
K535E and A539P, involved substantial changes in the
side-chain property. Such substitutions could produce
non-local perturbations on the channel structure and con-
sequently non-specific phenotype changes. A common
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reduction of the low pH current, suggesting that the re-
gion plays an important role in proton activation. S532M,
Q533E, S540L and M541L exerted little effect on either
CAPS or low pH responses. The CAPS activation and its
potentiation by low pH were not altered by the V538L,
E536W, K535E or A539P mutations at the macroscopic
level. V538L displayed a marked (>90% suppression) re-
duction in the maximal activity elicited by pH 4.5. Also
unlike T633A, which exhibited no measurable pH current
over the entire pH range, V538L furnished a titration
curve with a consistently increasing trend as the pH was
lowered. It appears that the mutation weakened, but did
not disrupt the pH gating completely. The V538L mutant
also exhibited a robust heat response.
The function of the channel appeared to be quite sen-
sitive to perturbations at position 538 (V538L, V538A,
V538G, V538I, V538T). Even the relatively conservative
substitution with Ala abrogated the low pH currents and
also reduced the CAPS activity. Further reduction of the
size of the side-chain with a substitution by Gly resulted
in non-functional channels [192].
In the experiments by Myers et al. [177], wild type
TRPV1 responded strongly to CAPS but displayed negli-
gible current under basal conditions or in response to
pH 6.4, which is at the threshold concentration required
for proton-evoked activation at room temperature. In
contrast, eight mutants (H166R, I352N, I352T, Q560R,
M562D, E684G, E684V, L792P), displayed a significant
response to pH 6.4, although no basal current was
detected at pH 7.4 Mammalian cell patch-clamp experi-
ments by Myers et al. demonstrated that F640L
displayed a strong basal channel activity and substantial
toxicity when expressed in HEK293 cells. Whereas the
wild type channel was potentiated by exposure to pH
6.2, the F640L current was completely unaffected under
these conditions. Addition of CAPS to F640L-expressing
cells led to a marked increase in current, demonstrating
that F640L channels are not maximally open in the
basal state. Higher doses of protons could activate the
mutant channel illustrating that while the mutant has
lost the ability to be potentiated within a certain pH
range, its proton activation has not been completely ab-
lated. Weakly alkaline solution (pH 8.2) failed to reduce
the F640L-mediated basal current. N628D and V658A
showed a potentiation effect under moderately acidic
conditions. Furthermore T641S and T650S mutants
displayed large constitutive channel activation with rela-
tive insensitivity to pH 6.4 [177].
Wang et al. reported that the first four TMs (TM1-4)
of TRPV1 dictate whether the activity of a fully CAPS-
bound receptor can be further enhanced by protons, and
a glutamate residue (E536) in the linker between TM3
and TM4 of hTRPV1 is critical in the modulation byprotons and in the further stimulation of fully liganded
TRPV1 [75,194].
Aneiros et al. [195] replaced amino acid F660 in
hTRPV1 (corresponding to F659 in rTRPV1) with a var-
iety of different amino acids (A, C, E, H, I, K, L, S, T, V,
W, Y) to determine the side-chain contribution to the
proton activation of TRPV1. Proton activation was ab-
lated by all amino acid replacements with the exceptions
of F660Y and F660W, the two alternative non-basic aro-
matic amino acids besides Phe. Replacing Phe with His
(F660H), which contains a basic aromatic ring (imid-
azole), or non-aromatic amino acids caused complete
loss of proton activation. However, F660Y demonstrated
a reduced sensitivity to proton activation as compared
with wild type TRPV1. Although less pronounced, the
maximum effect values at 1 μM CAPS were also reduced
relative to the wild type, while the CAPS EC50 values at
pH 7.4 were comparable. Ca2+ flux and whole-cell
patch-clamp experiments using HEK293 cells transiently
expressing TRPV1 mutants or wild type TRPV1 demon-
strated a complete lack of activation of the mutant
F660S by protons. In contrast, F660S maintained re-
sponsiveness to CAPS. TRPV1 mutant F660S ablated
proton activation, but not CAPS or heat activation.
F660A neither significantly inhibited nor significantly
potentiated CAPS responses in the presence of protons.
F660W showed a reduction in sensitivity to proton acti-
vation as well as CAPS activation similarly to F660Y.
These data suggest that a non-basic aromatic amino acid
at position 660 is essential for proton activation. A non-
aromatic amino acid or His at position 660 seems to be
tolerated for the channel to be functional in the CAPS
activation mode; a non-basic aromatic side-chain, how-
ever, appears to be required to maintain activation by
protons. The loss of activation by protons when F660 is
replaced with a charged amino acid and the absence of a
titration phenotype suggest that Phe is critical for the
transduction of proton-mediated gating rather than volt-
age or proton sensing. Aneiros et al. concluded that the
proton activation and potentiation of TRPV1 are both
voltage-dependent and that amino acid 660 is the key
residue regulating the proton-mediated gating of
hTRPV1 [195].
Mutations affecting voltage sensing
Susankova et al. [175] also checked the Ala-scaned region
of Y666-G683 for mutants disturbing the voltage sensor
function of the channel. To compare the effects of muta-
tions on voltage-dependent activation, Susankova et al.
used a voltage step protocol from −140 to +140 mV (in-
crement, +20 mV) at 25°C and normalized the resulting
current–voltage relationships at +60 mV for each cell.
Except for the T670A, Y671A and M677A, the Ala
mutations led to a rightward shift of the activation curve
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reflecting a decrease in channel activity at more negative
holding potentials (Figure 1).
These data indicate that most of the Ala mutations
modulate the gating of the TRPV1 by shifting the voltage
dependence toward more positive membrane potentials.
Temperature- and voltage-dependent mechanisms under-
lying the TRPV1 channel activation do not need to be
strictly coupled [175].
Voets et al. demonstrated the roles of K571, R575 and
R579 in voltage sensing using charge-neutralizing muta-
tions in TM4 and the TM4-TM5 linker of human
TRPM8 [172,196].
In the experiments of Boukalova et al. [179], the half-
maximal activation voltage (V1/2) of wild type TRPV1 was
154 ± 4 mV, and V1/2 was shifted towards less depolarizing
voltages for R557K (97.1 ± 4 mV), G563S (78 ± 2 mV),
and M581T (122 ± 11 mV). Mutations Y554A, Y555S,
E570L, R557E and R579E led to a complete loss of func-
tion, but three charge-swapping double mutants (R557E/
E570R, D576R/R579E and D576R/R579D) exhibited
measurable voltage-dependent activity, indicating a partial
recovery of the functionality of the R557E and R579E
mutant channels. To reveal the voltage-independent
component of TRPV1 gating, Boukalova et al. [179]
quantified V1/2 and the percentage of the voltage-
independent component of gating from currents
obtained in the presence of 10 μM CAPS. Significant
changes in the apparent gating valence were detected
in E570R and D576R/R579D, indicating that the
S4-S5 linker may increase its contribution to voltage
sensing when CAPS is present. R557A, R557L,
D576N and D576R, which were only weakly voltage-
dependent under control conditions, became as
voltage-sensitive as wild type TRPV1 in the presence
of CAPS, suggesting a preserved or even increased
allosteric effect between these two stimuli. Relative to
wild type TRPV1, the percentage of the voltage-
independent component of CAPS-induced gating was
found to be strongly reduced in R557A, R557L,
E570A, R579A, R579D, R557E/E570R and D576R/
R579E. In contrast, this component was predominant
in E570Q and E570R. G563S possesses an enhanced
voltage-dependent activity; inward currents induced by
1 μM CAPS exhibited slow activation kinetics and an in-
complete deactivation that was fully blocked by 1 μM
RuRed. G563S was not responsive to a temperature
ramp (from 25°C to 48°C) and was only weakly sensitive
to 300 μM 2-APB. These data suggest that the mutation
G563S stabilizes the open conformation of the channel
and thus G563 in TRPV1 could play an analogous role
in channel gating as in TRPV3 [179].
The F660S mutant in hTRPV1 (corresponding to
F659S in rTRPV1) was shown by Aneiros et al. tolack both voltage-dependent proton activation and po-
tentiation, whereas activation by heat or CAPS was
preserved [194,195].Mutations affecting antagonist or channel blocker action/
binding
I-RTX
S512 and M547 were tested by Johnson et al. [173] for
their potential involvement in I-RTX action.
I-RTX shows species-specific activity on TRPV1, as
well. The effect of the 547 residue on the ability of I-
RTX to antagonize the response of TRPV1 to 500 nM
CAPS was also challenged. As for RTX, the antagonist
I-RTX was found to be significantly more potent at
the rat receptor versus human receptor. After substi-
tution of the rat-specific Met into the human con-
struct (L547M), I-RTX gained functional potency,
although the converse change (M547L) showed little
effect (Figure 1). Introduction of the Met residue thus
enables the human receptor to interact more effect-
ively with both agonist and antagonist alike in a man-
ner that is not matched by Leu.
S512Y was found to convert I-RTX from an antagonist
to an agonist with nanomolar potency, albeit with much
lower efficacy than its counterpart (RTX) for the wild
type channel. Other agonists such as CAPS or acidifica-
tion with pH 5.8 was shown to enhance the agonist po-
tency of I-RTX, producing a 20-fold decrease in the
EC50 value [173].RuRed
D646N was reported by Garcia-Martinez et al. to de-
crease the efficacy of RuRed to block the channel by 10-
fold [197] (Figure 1).Mutations affecting spider venoms action/binding
Venoms from spiders, snakes, scorpions and cone
snails can cause burning pain. Small peptides, named
vanillotoxins (VaTx) and “double-knot” toxin (DkTx)
were indentified as TRPV1 agonists from the venoms
of the spiders Psalmopeous cambridgei and
Ornithoctonus huwena, respectively. Alanin scanning
of the region S592-A665 revealed three sites (I599A,
F649A, and F659A) where alanin substitutions caused
reduced toxin responses (Figure 1). A657P and
A657W also showed loss of toxin sensitivity. Xenopus
laevis xTRPV1 also contains Pro at the extracellular
boundary of the S6 domain, corresponding to amino
acid A657 of rTRPV1, and is insensitive to VaTx or
DkTx, but responds to CAPS and low pH. The recip-
rocal mutant (P663A) conferred toxin responsiveness
of the frog TRPV1. The quadruple mutant (I599A/
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sensitivity [198,199].
The venom from the spider Agelenopsis aperta, a
North American funnel web spider, contains potent in-
hibitors of TRPV1. Two acylpolyamine toxins, AG489
and AG505, inhibit TRPV1 from the extracellular side of
the membrane [200]. To identify mutations that alter
these toxin affinity, Kitaguchi and Swartz [200] Trp
scanned the TM5-TM6 linker region from Y627 to E651,
mutating 25 consecutive residues to Trp. Of these mu-
tants, 15 resulted in channel expression that could read-
ily be studied by using electrophysiological techniques,
whereas 10 produced little or no CAPS-activated current
and were not studied further. One residue in this region
(D646) was also mutated to Asn. The D646W mutant
did not yield functional channel. N628W, E636W,
D646N and E651W dramatically decreased toxin affinity.
Mutations of Y627W , C634W and to a lesser extent
F638W, L647W and F649W enhanced the sensitivity to
the toxin [200]. According to these results and previous
studies on polyamine inhibitors of cation channels,
AG489 seemed to be a pore blocker.
Sites of action of negative or positive modulators
A number of studies have demonstrated that the cyto-
plasmic regions of TRP channels bind agonists and
regulatory molecules such as ATP, CaM and PIP2
[14,95,107,201-204].
ATP
Kwak et al. [205] found that D178N substitution abolished
the ATP-mediated upregulation of TRPV1. Mutations
generated by Lishko et al. [14], K155A and K160A, and
the double mutation Y199A/Q202A impaired the
TRPV1-ARD interaction with ATP. TRPV1 channels with
mutations in the ATP-binding site (K155A, K160A, or
Y199A/Q202A) showed little tachyphylaxis, even in the
absence of ATP, while the two negative control mutants
(R181A and K265A) had essentially wild type behaviour
(Figure 1). The lack of tachyphylaxis shown by the TRPV1
mutants was not due to an impaired CAPS sensitivity; in
fact, the mutant channels were slightly more sensitive to
CAPS than the wild type channel [14,46].
Ca2+/CAM
Ca2+/CaM has been reported to bind to peptides from
the N-terminal region of TRPV1, and that the residues
189-221 are crucial determinants for binding [107].
Grycova et al. [206] found that the CaM-binding site
overlapped with the PIP2-binding site in the C-terminal
distal region (L777-S820) and that PIP2 interacted with
the proximal region (I688-K718) of the TRPV1 C-
terminal (Figure 1).Lishko et al. [14] found that the TRPV1-ARD mutants
K155A and K160A, which no longer bind ATP, did not
interact with CaM in size exclusion chromatography,
emphasizing that the binding surface on TRPV1-ARD is
at least partially shared by both ligands.
The TRPV1-ARD Y199A/Q202A mutant, where resi-
dues important for interactions with the adenine moiety
of ATP were mutated, formed a weaker complex with
CaM that eluted earlier than the complex with wild type
TRPV1-ARD, still had a 1:1 stoichiometric ratio,
suggesting that the different elution properties may be
due to an altered conformation or binding constant, or
higher-order (e.g., 2:2) complex [14].
PIP2
PIP2 has been shown to physically interact with a C-
terminal fragment of TRPV1 [203]. In the experiments
of Brauchi et al. [191] the mutation of the positively
charged R701 and K710 to Ala strongly affected the
PIP2-dependent activation, shifting the dose–response
curves to the right along the concentration axis [191]
(Figure 1).
Grycova et al. [206] showed that two different PIP2-
binding sites on the C-terminus L777-S820 and the N-
terminus F189-V221 overlapped with the CaM-binding
sites, and the third PIP2-binding site K688-K718 occu-
pied the TRP domain on the C-terminus, a highly con-
served sequence among the members of the TRP ion
channel family. The presence of PIP2 was reported to
prevent the interaction of the distal region of the C-
terminus with CaM, which could play an important role
in the regulation of TRPV1. To identify the residues im-
portant for the binding of PIP2 to TRPV1-C-terminus, a
set of point mutations was generated by Grycova et al.,
involving the single substitutions R778A and R781A,
the double substitutions K770A/R785A, R771A/R781A
and R771A/R778A and the triple substitutions K770A/
R778A/R785A and K770A/R781A/R785A. The most
striking effect was the total loss of binding affinity ob-
served for the single mutant R778A, the double mutant
R771A/R778A and the triple mutant K770A/R778A/
R785A. Moreover, the K770A/R785A and R771A/
R781A mutations decreased the binding affinity. The
K694A/K698A/K710A triple mutant seemed to com-
pletely lose its ability to bind PIP2. Ala substitutions of
the additional candidate residues in the highly conserved
QRA region Q700A/R701A significantly attenuated its
binding affinity for PIP2. These data show that the
TRPV1 C-terminal proximal region (K688-K718) binds
PIP2 directly with a high affinity and suggest that basic
residues play a crucial role in the binding.
The steady-state anisotropy measurements by Grycova
et al. confirmed that the region denoted as a CaM inter-
action site F189-V221 binds PIP2 with high affinity. On
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acting with the TRPV1 C-terminal distal region, Grycova
et al. suggested that the phosphate head groups of PIP2
form polar interactions with positively charged Arg resi-
dues R778, R781, R785. PIP2 thus occupies the CaM
binding groove containing R771, R778, R781, R785 de-
scribed previously [201]. Residues R778 and R781 were
found to have key role in the binding of PIP2. Further
combinations of Ala substitutions revealed that the
TRPV1-CT distal region participates in PIP2 binding
through a cluster of basic residues: the double and triple
substitutions of R771A/R778A and K770A/R778A/
R785A avoided PIP2 binding totally, and the K770A/
R785A and R771A/R781A mutations suppressed this
interaction partially. Site-directed mutation of R701 Arg
reduced the binding affinity for PIP2. The triple substi-
tution at positions K694A/K698A/K710A had the most
pronounced effect, preventing PIP2 completely from
binding to this region. The regions F189-V221 within
the N-terminus and K688-K718 and L777-S820 within
the C-terminus are involved in PIP2 binding. Interest-
ingly, the F189-V221 and L777-S820 regions overlap
with the CaM-binding sites, suggesting that CaM and
PIP2 compete for the same binding site, which might
have implications for regulation of the channel function.
R778A was found to have the key role in the inter-
action. This single mutation leads to a total loss of bind-
ing affinity of the distal C-terminal region [206].Reducing agents
DTT, an agent that maintains the -SH groups of Cys in a
reduced state, has been reported to facilitate membrane
currents through TRPV1 when applied from the extra-
cellular face of the channel, by interacting with the resi-
dues at positions C616, C621 and C634 in the loop
between the fifth and sixth transmembranal domains
[207] (Figure 1).
Site-directed mutagenesis experiments in the pore loop
have identified C621 as the residue responsible for the
extracellular modulation of TRPV1 by reducing agents
[112]. Mutations C616G and C634G did not affect DDT
potentiation at 45°C, but C621G and the triple mutant
C616G/C621G/C634G significantly reduced DDT po-
tentiation without having any effect on the CAPS, heat or
voltage gating of the channel [78,112].Cholesterol
Using measurements of CAPS-activated currents in ex-
cised patches from TRPV1-expressing HEK293 cells,
Picazo-Juárez et al. [208] showed that enrichment with
cholesterol, but not its diastereoisomer epicholesterol,
markedly decreased wild type rTRPV1 currents in the
presence of CAPS, elevated temperature or voltage.Substitutions in the S5 helix by Picazo-Juárez et al.
[208], R579D and F582Q, decreased the cholesterol re-
sponse and L585I was insensitive to cholesterol addition
(Figure 1). Two hTRPV1 variants, with different amino
acids at position 585, displayed different responses to
cholesterol, with hTRPV1-I585 being insensitive to this
molecule. However, hTRPV1-L585 was inhibited by
cholesterol addition similarly to rTRPV1 with the same
S5 sequence (containing L585). In the absence of CAPS,
cholesterol enrichment also inhibited the TRPV1 cur-
rents induced by elevated temperature and voltage.
The amino acids in positions K571, R575 and R579
were confirmed to be involved in TRPV1-lipid interac-
tions [172,191].
Mutations of phosphorylation sites
Phosphorylation by PKC, which potentiates CAPS, acid,
and thermal responses in TRPV1 channels, occurs at
two target Ser residues (S502 and S800) [78,85,209]
(Figure 1). Residues located in the N-terminus of TRPV1
(S116 and T370) are phosphorylated by PKA and have
been implicated in desensitization [85,176,210] whereas
residues T144, T370 and S502 have been implicated in
the sensitization of heat-evoked TRPV1 responses when
phosphorylated by PKA [78,83]. Phorbol 12-myristate
13-acetate (PMA), a PKC-activating phorbol, was observed
to decrease the binding of [3H]RTX to TRPV1 [115]
through interaction withY704 in the C-terminus [46,85].
The site-directed mutation of residue S116A per-
formed by Wang et al. [90] was reported to block both
the phosphorylation of rTRPV1 by PKCμ and the
enhancement by PKCμ of the response of rTRPV1 to
CAPS. Ser116 is also a major phosphorylation site in
TRPV1 for PKA, and this site has been shown to be in-
volved in TRPV1 desensitization [116].
Numazaki et al. [174] observed that, when S502 and
S800 residues were replaced with Ala, the TRPV1 activ-
ity induced by CAPS, protons or heat was eliminated
[78]. S502A was found to significantly reduce PMA en-
hancement of CAPS-evoked currents, but had no effect
on direct activation by PMA [91].
CaMKII regulates TRPV1 activity through the phos-
phorylation of two residues: S502 and T704 [46,91].
Phe mutations of the hTRPV1 Y195, Y199, Y375, Y383
and Y402 did not diminish Src kinase dependent phos-
phorylation. But when Y200 (corresponding to Y199 in
rTRPV1) was mutated, Src-dependent, NGF-induced Tyr
phosphorylation was completely abolished [211].
A glycosylation site (N604) was identified by Wirkner
et al. [172,212].
Mutations affecting divalent cations
Site-specific analysis has shown that substitutions of D646
or Y671 in the pore domain can reduce the permeability
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ivity is dynamic, not static, and can vary depending on the
stimulus duration or agonist concentration. Activation
can alter the Ca2+ permeability and pore diameter of
TRPV1 to allow influx of larger cations. This change in
permeability is mediated by amino acid residues in TM6.
Within this domain, L681 can regulate the permeability of
large cations, while Y671 gates the access of smaller cat-
ions [169,178]. Our group discovered a blocking effect of
divalent heavy metal cations and especially of Co2+ on
rTRPV1 [213]. The effects of the cations were evaluated
in rTRPV1 containing mutations reported earlier in con-
text of proton activation and tarantula toxin effect. The
Co2+ sensitivity was slightly reduced in the D646N mu-
tant. TheY627W, N628W and E651W mutants displayed
little or no difference as compared with the wild type
channel [213].
Mutations of structural involvement
Deletion studies have shown that the C-terminal TRP
domain (E684-R721) regulates the formation of func-
tional channel tetramers [214]. Removal of this region
prevents the oligomerization into stable TRPV1
heteromers [169].
Mutations causing heightened base activity
Constitutively active TRPV1 mutants might harbor
deficits in some aspect of channel activation, and a
comprehensive list of such mutations could provide
valuable information about the location of the chan-
nel gate.
Jordt et al. [43] showed that HEK293 cells expressing
E600Q TRPV1 channels showed markedly reduced via-
bility. Replacement of this Glu residue with Gln
(E600Q) or a positively charged amino acid (E600K)
resulted in a significant level of cell death in HEK293
cells expressing these mutant channels, over their
heightened activity under normal culture conditions,
whereas substitution with an acidic residue (E600D) was
not deleterious (Figure 1). This observation suggested
that a decrease in negative charge at the E600 site fa-
vours channel activation. The E600K mutant showed a
most dramatic sensitization phenotype. These channels
were already activated at temperature thresholds (30–32°
C) well below normal (43°C), resembling the heat sensi-
tivity of wild type channels at pH 6.3 [43].
By genetic screening of a randomly generated popula-
tion of TRPV1 mutants, Myers et al. [177] demonstrated
that mutations within the pore helix domain dramatic-
ally increased basal channel activity and responsiveness
to chemical and thermal stimuli. The screening for gain
of function mutations revealed a total of 30 unique mu-
tations at 25 amino acid positions: C73S, K160E,
S343R, A350T, Q561R, M581T, M609T, F640L,N652D, L673I, E684G, E684V, K710R, F742S, W787R
and L796P caused strong toxicity when expressed in
Saccharomyces cerevisiae, whereas other gain of function
mutations I75F, I76T, V78G, K155E, H166R, N310D,
S343G, I352N, I352T, Q560R, M609V, I689V, L792P
and L796V elicited weak toxicity to the cells.
Some mutants displayed large basal currents at pH
7.4, which could be blocked by RuRed. The authors clas-
sified mutants as constitutively active when the ratio of
the basal inward currents and the CAPS-elicited cur-
rents exceeded 0.15 (Ibasal/Icap ≥ 15%). The mutants
K155E, K160E, M581T and F640L achieved a rank con-
stitutively active.
F640L displayed the strongest basal channel activation,
and conferred substantial toxicity when expressed in
HEK293 cells, characterized by necrotic morphology
similar to that observed in cells expressing wild type
TRPV1 after prolonged exposure to CAPS. Inclusion of
RuRed (3 mM) in the culture medium significantly at-
tenuated the death of F640L-expressing cells.
Inside-out patches from the F640L mutant displayed
large basal currents with a substantial inward compo-
nent but CAPS at saturating concentrations elicited cur-
rents of similar magnitude to those evoked in patches
containing wild type channels.
Myers et al. found no significant difference in either
the single-channel conductance or the relative perme-
abilities for Na+, K+, and Ca2+ ions when comparing wild
type and F640L mutant channels, showing that the
F640L mutation affects gating rather than permeation
properties. Consistent with a hypersensitive gating
mechanism, F640L mutant displayed a 35-fold leftward
shift in the CAPS dose-response curve compared to the
wild type receptor, the basal current however, was
suppressed by CapZ demonstrating that the high consti-
tutive activity is not due to an inability of the channel to
close. Consequently, the gating machinery seems to re-
main intact in the F640L mutant, but the equilibrium
appears to be shifted to favor the open state. F640L mu-
tation enhances sensitivity to heat and CAPS by shifting
the stimulus- response relationships of the channel left-
ward while also decreasing apparent cooperativity of
gating.
To fully explore the structural requirements at pos-
ition F640 a codon randomization was performed. Most
substitutions at this position, particularly those of a
hydrophilic nature, weakened or abolished channel activ-
ity. F640K, F640Q, F640S, F640H, F640Y weakly,
whilst F640C, F640E, F640G, F640N, F640R, F640D,
F640P strongly decreased channel function. Further-
more, F640A and F640T represented an intermediate
phenotype between wild type and weak loss of function.
In contrast, several hydrophobic amino acids supported
wild type functionality (F640M, F640V, F640W), except
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channels (F640L, F640I). Thus this codon randomization
illustrated that most hydrophobic substitutions at F640
produced functional channels, whereas two small hydro-
phobic residues supported constitutive channel activity,
suggesting that F640 is buried in a non-polar environ-
ment. Myers et al. uncovered nine additional substitutions
conferring a toxic phenotype in yeast (N625D, N628D,
C634S, T641S, T650S, K656E, K656Q, V658A and
F659Y). These mutants were unable to grow on replica
plates containing CAPS but no RuRed. Of these, two
(T641S and T650S) showed high basal activity. Interest-
ingly, T641S (and, to a lesser extent, T650S) mutants
displayed large constitutive channel activation with rela-
tive insensitivity to pH 6.4 [177].
Mutations having deleterious effects on channel function
The E610Q mutants exhibited relatively small responses
to any stimuli (CAPS, heat or pH), suggesting that this
substitution had deleterious effects on the channel func-
tion at large [43]. The function of the channel appeared
quite sensitive to perturbations at the position V538
(Figure 1). Substitution with Gly (V538G) resulted in
non-functional channels [192]. Susankova et al. [175]
mutated and examined the residues Y666-G683 of
TRPV1. Y666A and N676A showed no CAPS-, pH- or
heat-evoked activity and exhibited no currents in re-
sponse to 47°C and 30 μM CAPS applied together. They
were determined to be non-functional mutants,
suggesting that these two residues within the inner-pore
region of rTRPV1 are critical for channel functionality.
Boukalova et al. [179] identified mutations Y554A,
Y555S and E570L and two charge-reversing mutations,
R557E and R579E, that led to a complete loss of func-
tion. In these mutants, 10 μM CAPS neither induced
measurable currents at a holding potential of −70 mV,
nor affected voltage-dependent (up to +200 mV) or
heat-dependent currents (up to 48°C). The Y554F and
Y555F mutations produced fully functional channels,
indicating that aromatic side-chains are required at
these positions.
Mutations providing structural information of the channel
without having phenotype
Ryu et al. investigated mutations of other residues
(D601-S611, Y627-F640 and D646-E651) that had
minimal consequences, leaving CAPS and low pH re-
sponses mostly intact. These included radical perturba-
tions such as the charge mutations N628R and S632D,
suggesting that these residues are probably exposed to
the aqueous phase. Such an arrangement would be con-
sistent with their positions in a helix, which renders
T633 facing away from the aqueous phase, making it ac-
cessible to interaction with other residues [192]. Thefunction of the channel appeared quite sensitive to per-
turbations at the position 538 (V538L, V538A, V538G,
V538I, V538T). Even the relatively conservative substi-
tution with Ala abrogated the low pH currents and also
reduced the CAPS activity. Further reduction of the size
of the side-chain with a substitution by Gly resulted in
non-functional channels. It appeared that the local struc-
ture of the channel lacks rigidity to tolerate a smaller
side-chain at this position. However, the size of the side-
chain was not the only factor determining the function
of the residue. Replacement by Ile, which has the same
volume as Leu, recovered a small, but significant portion
of the low pH activity. The data appeared to consist of
two populations, one similar to the wild type and the
other to V538L, as if the local structure of the channel
existed in some metastates. Finally, Thr substitution,
which preserved the side-chain size, did not confer the
wild type responses either. Together, these data indicate
that multiple aspects of the side-chain, including both
volume and steric hindrance are important for the func-
tion of the residue [192].
Deletion mutants
An N-terminus deletion mutant by Jung et al. [16], Δ1–109,
which elicited Icap, retained specific binding for [
3H]RTX.
In contrast, cells expressing Δ1–114, which failed to show
Icap, completely lost their specific binding to [
3H]RTX.
Similarly, deletion mutants at the C terminus, such as
Δ762–838 and Δ763–838, which displayed smaller Icap, bound
[3H]RTX similarly to the wild type. In contrast, Δ761–838,
which failed to elicit Icap, had no ability to specifically bind
[3H]RTX. Deletion mutants that lacked one of these two
regions lost current sensitivity to CAPS and the ability to
bind ligands. The two regions in the vicinity of R114 and
E761 are critical for ligand binding and that the loss of
these regions abrogates vanilloid activation. A deletion as
small as a single amino acid affects the ligand binding.
Δ114 and Δ761 failed to elicit CAPS-sensitive inward cur-
rents. Furthermore, the mutants did not show specific
binding to [3H]RTX. Both mutants elicited whole-cell cur-
rents when activated by heat at ~46°C, but both mutants
failed to respond to acid (pH 5.5) [16].
Deletion of a Thr residue in TM4 (ΔT550) reduced
CAPS sensitivity [171] (Figure 1).
To investigate the contribution of the pore turret to
the TRPV1 function, Cui et al. [190] generated a series
of turret deletion mutations by deleting the first 10
(ΔG603-S612), 17 (ΔG603-G619), or all 24 amino acids
(ΔG603- N626), and also deleted seven amino acids from
the C-terminal end of the turret (ΔS620-N626).
ΔG603-S612 mutant channel was found to be functional,
and exhibited nearly identical CAPS sensitivity to that of
the wild type. As CAPS exhibited very similar potency
and efficacy in activating wild type and ΔG603-S612
Table 1 Summary table of the mutants discussed in the article
Residue Mutated to Role in the channel function / Impact of the mutation on the channel function Refs
C73 S Its mutation caused gain of function and strong toxicity when expressed in
Saccharomyces cerevisiae.
[177]
I75 F Its mutation caused gain of function mutation and weaker toxicity when expressed in
Saccharomyces cerevisiae.
[177]
I76 T Its mutation caused gain of function mutation and weaker toxicity when expressed in
Saccharomyces cerevisiae.
[177]
V78 G Its mutation caused gain of function mutation and weaker toxicity when expressed in
Saccharomyces cerevisiae.
[177]
R114 A, E, Δ Its deletion or mutation abrogated vanilloid and proton activation and RTX binding,
without effecting heat activation.
[16]
R115 D Its mutation abrogated vanilloid activation and RTX binding, without effecting heat
activation.
[16]
S116 A The residue is phosphorylated by PKA and is involved in desensitization. It is also
functional target for PKCμ. Its mutation abolished phosphorylation by PKCμ and
enhanced the channel response to CAPS by PKCμ.
[85,90,176,210]
T144 Its phosphorylation by PKA causes sensitization of heat-evoked responses. [78,83]
K155 A, E Its mutation caused impaired TRPV1-ARD interaction with ATP, and impaired
tachyphylaxis, even in the absence of ATP. The mutant channel did not interact with
CaM, and was slightly more sensitive to CAPS than the wild type.
[14,177]
Its mutation resulted in a constitutively active channel, and caused gain of function
mutation and weaker toxicity when expressed in Saccharomyces cerevisiae.
C157 The residue is covalently modified by allicin causing allicin activation of the channel. [187]
K160 A, E Its mutation caused impaired TRPV1-ARD interaction with ATP, and impaired
tachyphylaxis, even in the absence of ATP. The mutant channel did not interact with
CaM, and was slightly more sensitive to CAPS than the wild type.
[14,177]
Its mutation resulted in a constitutively active channel, caused gain of function
mutation and strong toxicity when expressed in Saccharomyces cerevisiae.
H166 R Its mutation caused gain of function mutation and weaker toxicity when expressed in
Saccharomyces cerevisiae. Its mutation resulted in significant response to pH 6.4
(threshold concentration for proton-activation).
[177]
D178 N Its mutation abolished the ATP-mediated upregulation of TRPV1. [205]
Y199 A, F When both sites were mutated, Y199/Q202 impaired the TRPV1-ARD interaction with
ATP and ATP-mediated tachyphylaxis. The mutated channel was slightly more sensitive
to CAPS than the wild type. Mutant channels formed a weaker complex with CaM than
wild type but it still had a 1:1 stoichiometric ratio.
[14,211]
Phosphorylation of hTRPV1 Y200 (Y199 in rTRPV1) by Src kinase increases the surface
expression of TRPV1 and accounts for rapid sensitizing actions of NGF. When mutated,
Src-dependent, NGF-induced Tyr phosphorylation was completely abolished.
Q202 A When both sites were mutated, Y199/Q202 impaired the TRPV1-ARD interaction with
ATP and ATP-mediated tachyphylaxis. The mutated channel was slightly more sensitive
to CAPS than the wild type. Mutant channels formed a weaker complex with CaM than
wild type but it still had a 1:1 stoichiometric ratio.
[14]
N310 D Its mutation caused gain of function and weaker toxicity when expressed in
Saccharomyces cerevisiae.
[177]
S343 G, R, Its mutation caused gain of function and strong/weak toxicity when expressed in
Saccharomyces cerevisiae.
[177]
A350 T Its mutation caused gain of function and strong toxicity when expressed in
Saccharomyces cerevisiae.
[177]
I352 N, T Its mutation caused gain of function mutation and weaker toxicity when expressed in
Saccharomyces cerevisiae. Its mutation also caused significant response to pH 6.4
(threshold concentration for proton-activation).
[177]
T370 The residue is phosphorylated by PKA. It is involved in desensitization of the channel,
and in the sensitization of heat-evoked TRPV1 responses when phosphorylated by PKA.
[78,83,85,176,210]
F489 Y Mutation resulted in a rightward shift of the CAPS concentration of half-maximal
activation.
[167]
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R491 E, G, Mutation caused reduction in CAPS sensitivity. [168]
S502 A Its phosphorylation by PKC potentiates CAPS, proton, and thermal responses, and that
by PKA sensitizes the heat-evoked responses.
[78,83,85,91,174,209]
It is a CaMKII phosphorylation site.
When associated with T704I, S502A was found to lose the ability to be activated by
CAPS and to lose the ability of vanilloid binding.
Its mutation reduced PMA enhancement of CAPS-evoked currents, but had no effect
on direct activation by PMA.
Y511 A, C, F, Its mutation abolished CAPS responses, and RTX binding yet leave activation by heat
and protons intact.
[168-171,180]
S512 A, F, T, Y Its mutation abolished CAPS responses and RTX binding, yet left activation by heat and
protons intact. It is involved in I-RTX binding.
[168,169,173,193]
Q519 N Its mutation ablated the vanilloid sensitivity. [168]
F522 L Its mutation ablated the vanilloid sensitivity. [168]
M523 L Its mutation ablated the vanilloid sensitivity. [168]
S532 C Its mutation ablated the vanilloid sensitivity. [168]
K535 E Its mutation ablated the vanilloid sensitivity, and affected proton responses. [168,192]
E536 L, W Its mutation ablated the vanilloid sensitivity, and affected proton responses. [168,192]
V538 A, G, I, L, T Its mutation ablated proton activation, but not the proton potentiation. [192]
A539 P Its mutation affected proton responses. [192]
M547 A, I, L, Q The residue is involved in RTX binding, CAPS sensitivity, I-RTX sensitivity and proton
sensitivity.
[168,170,171,173,180]
W549 It is involved in vanilloid binding. [171,182]
T550 A, C, I, S, Y, Δ, It is an important molecular determinant in vanilloid sensitivity. Participates in Caps
and RTX binding.
[168,170,171,180]
Its deletion reduced CAPS sensitivity of the channel.
R557 A, E, K, L It is involved in CAPS potentiation of heat-induced currents and in the transduction of
the CAPS-binding signal to the opening of the pore.
[179]
It is also important in deactivation gating process, 2-APB activation and for voltage-
dependent gating.
It contributes to the voltage modulation of the CAPS-induced currents and the CAPS
potentiation of the heat-induced currents.
Q560 H, R It is involved in the transduction of the CAPS-binding signal to the opening of the pore. [177,179]
It is also important in deactivation gating process and for 2-APB activation.
Its mutation caused significant response to pH 6.4 (threshold concentration for proton-
activation).
Its mutation caused gain of function of the channel and weaker toxicity when
expressed in Saccharomyces cerevisiae.
Q561 H, R Its mutation caused gain of function of the channel and strong toxicity when
expressed in Saccharomyces cerevisiae.
[177]
M562 D Its mutation caused significant response to pH 6.4 (threshold concentration for proton-
activation).
[177]
G563 S The residue is involved in the voltage gating of the channel. [179]
E570 A, L, Q, R The residue contributes to the voltage modulation of the CAPS-induced currents and
the CAPS potentiation of the heat-induced currents.
[179]
It is involved in the transduction of the CAPS-binding signal to the opening of the
pore and in the 2-APB activation of the channel.
It is also a relevant heat-sensing factor.
K571 E The residue is a specific binding site for 2-APB. [172,179,191,196]
It is involved in voltage sensing and in TRPV1-lipid interactions.
R575 A The residue is involved in voltage sensing and in TRPV1-lipid interactions. [172,191,196]
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D576 N, R The residue is involved in the voltage-dependent gating of TRPV1, and contributes to
the voltage modulation of the CAPS-induced currents and the CAPS potentiation of
the heat-induced currents.
[179]
It contributes to the transduction of the CAPS-binding signal to the opening of the pore.
R579 A, D, E The residue contributes to the voltage modulation of the CAPS-induced currents and to the
CAPS potentiation of heat-induced currents. It is involved in the voltage sensing and in
TRPV1-lipid interactions. Its mutation decreased the cholesterol response of the channel.
[172,179,191,196,208]
M581 T The residue contributes to the transduction of the CAPS-binding signal to the opening
of the pore, and to the deactivation gating process. It is involved in voltage gating.
[177,179]
Its mutation caused gain of function of the channel and strong toxicity when
expressed in Saccharomyces cerevisiae.
F582 Q Its mutation decreased the cholesterol response of the channel. [208]
L585 I Its mutation abolished the cholesterol response of the channel. [208]
I599 A Its mutation caused reduced DkTx responses. [207]
E600 A, D, H, K, Q, S, V The residue is involved in the proton potentiation, but not in proton activation. [43,167]
Its mutation to neutral or positive residues potentiates responses to CAPS or heat, and
introduction of a residue with lower pKa decreased the channel sensitivity to CAPS or heat.
D601 N Its mutation reduced the proton-activated currents significantly, without altering the
heat- or CAPS-evoked responses, and without eliminating the ability of protons to
potentiate the responses to these stimuli.
[43]
M609 T, V Its mutation caused gain of function of the channel and strong/weak toxicity when
expressed in Saccharomyces cerevisiae.
[177]
C616 G The residue is involved in DTT interaction. [78,112,207]
C621 G The residue is responsible for the extracellular modulation of TRPV1 by reducing
agents. It is involved in DTT interaction. Its mutation and when associated with C616G
and C634G significantly reduced DDT potentiation without having any effect on the
CAPS, heat or voltage gating of the channel.
[78,112,207]
N625 D Its mutation caused toxicity when expressed in Saccharomyces cerevisiae. [177]
Y627 A, W The residue contributes to, but do not play a pivotal role in the proton activation. Its
mutation enhanced the sensitivity to the acylpolyamine toxins AG489 and AG505.
[192,200]
N628 D, K, R, W The residue plays essential roles in the heat response without affecting the CAPS
responses or the desensitization of the channel. It is involved in proton-induced
potentiation. Its mutation reduced the heat responses in amplitude and shifted them to
higher temperatures, dramatically decreased the sensitivity to the acylpolyamine toxins
AG489 and AG505 and caused toxicity when expressed in Saccharomyces cerevisiae.
[167,177,192,200,213]
S629 A The residue contributes to, but do not play a pivotal role in the proton activation. [192]
T633 A, S, V Its mutation eliminated the proton-activated currents while leaving normal responses
to CAPS and low pH potentiation. Its mutation exhibited a weaker response to heat in
amplitude, however, the thermal activation threshold was unchanged.
[192]
C634 G, S, W It is involved in DTT interaction, its mutation and when associated with C616G and
C621G significantly reduced DDT potentiation without having any effect on the CAPS,
heat or voltage gating of the channel. Its mutation also enhanced the sensitivity to the
acylpolyamine toxins AG489 and AG505, and caused toxicity when expressed in
Saccharomyces cerevisiae.
[78,112,177,200,207]
E636 Q, W The residue is a specific contributor to the CAPS response without affecting the proton
or thermal sensitivity. Its mutation dramatically decreased the sensitivity to the
acylpolyamine toxins AG489 and AG505.
[43,165,200]
F638 W Its mutation enhanced the sensitivity to the acylpolyamine toxins AG489 and AG505. [200]
F640 A, C, D, E, G, H, I, K, L, M, N,
P, Q, R, S, T, V, W, Y,
The residue is critical for heat activation. Its mutation was constitutively active, and
caused strong toxicity when expressed in Saccharomyces cerevisiae. Its mutation also
enhanced the sensitivity to heat and CAPS, and abolished the proton potentiation of
the channel. This mutation affected gating rather than permeation properties of the
channel.
[177]
T641 S The residue is involved in acid activation and potentiation. Its mutant displayed large
constitutive channel activation and caused toxicity when expressed in Saccharomyces
cerevisiae.
[177]
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D646 N, W The residue is a specific contributor to the CAPS response without affecting the proton
or thermal sensitivity, and it is engaged in inhibition by RuRed. Its mutation reduced
the permeability of divalent cations and dramatically decreased the sensitivity to the
acylpolyamine toxins AG489 and AG505.
[43,165,176,197,213]
L647 W Its mutation enhanced the sensitivity to the acylpolyamine toxins AG489 and AG505. [200]
E648 A, Q The residue is a specific contributor to the CAPS response without affecting the proton
or thermal sensitivity. Its mutation reduced the proton-activated currents significantly,
without altering the heat- or CAPS-evoked responses, and without eliminating the
ability of protons to potentiate the responses to these stimuli.
[43,165]
F649 A, W Its mutation caused reduced DkTx responses, and enhanced the sensitivity to the
acylpolyamine toxins AG489 and AG505.
[198,200]
T650 S The residue is involved in proton-induced potentiation. Its mutation caused large
constitutive channel activation with abolished pH sensitivity. Its mutation caused
toxicity when expressed in Saccharomyces cerevisiae.
[177]
E651 Q, W The residue is important in pH activation. Its mutation dramatically decreased the
sensitivity to the acylpolyamine toxins AG489 and AG505.
[43,192,200,213]
N652 D, T The residue plays essential roles in the heat response without affecting the CAPS
responses or the desensitization of the channel. Its mutation reduced the heat responses
in amplitude and shifted them to higher temperatures. Its mutation also caused gain of
function and strong toxicity when expressed in Saccharomyces cerevisiae.
[167,177]
Y653 T The residue plays essential roles in the heat response without affecting the CAPS
responses or the desensitization of the channel. Its mutation reduced the heat
responses in amplitude and shifted them to higher temperatures.
[167]
K656 E, Q Its mutation caused toxicity when expressed in Saccharomyces cerevisiae. [177]
A657 P, W The residue is critical for DkTx binding, its mutation showed loss of DkTx sensitivity. [197]
V658 A The residue is involved in acid potentiation. Its mutation showed a potentiation effect
under moderately acidic conditions. Its mutation also caused toxicity when expressed
in Saccharomyces cerevisiae.
[177]
F659 A, C, E, H, I, K, L, S, T, V,
W, Y
The residue is involved in proton activation, and is a key integrator of voltage sensing,
proton activation and potentiation. Its mutation caused lack of both voltage-
dependent proton activation and potentiation, whereas activation by heat or CAPS
was preserved. Its mutation caused reduced DkTx responses and caused toxicity when
expressed in Saccharomyces cerevisiae.
[177,194,195,198,199]
Y666 A Its mutation resulted in non-functional channel. [175]
I668 A Its mutation reduced CAPS sensitivity, heat-induced current responses and heat-
potentiated CAPS currents.
[175]
L669 A The residue is involved in heat activation but not in CAPS activation, nor in the heat
potentiation of the CAPS currents.
[175]
Y671 A The residue might contribute to allosteric coupling between temperature- and CAPS-
dependent activation mechanisms. Its mutation affected the heat-induced current
responses, lowered the CAPS EC50 value of the channel. Responses to CAPS were not
potentiated by heat in the mutant containing channel, in fact CAPS-evoked responses
were inhibited by heat. The residue is involved in the regulation of permeability of
divalent cations, it gates the access of smaller cations.
[169,175,176,178,197]
I672 A Its mutation reduced CAPS sensitivity, heat-induced current responses and heat-
potentiated CAPS currents.
[175]
L673 A, I Its mutation caused gain of function and strong toxicity when expressed in
Saccharomyces cerevisiae. Its mutation also reduced CAPS sensitivity, heat-induced
current responses and heat-potentiated CAPS currents.
[175,177]
L674 A Its mutation reduced CAPS sensitivity, heat-induced current responses and heat-
potentiated CAPS currents.
[175]
L675 A Its mutation reduced CAPS sensitivity and heat-potentiated CAPS currents. [175]
N676 A, F Its mutation influenced the ability of CAPS and RTX to activate TRPV1 without
changing the response of the channel to protons. Its mutation to Ala resulted in non-
functional channel.
[166,175]
M677 A Its mutation in a triple mutant (N676F/M677A/L678P) influenced the ability of CAPS
and RTX to activate TRPV1 without changing the response of the channel to protons.
Its mutation alone blunted heat-induced current responses without a significant
change of CAPS- or heat-potentiated CAPS currents.
[166,175]
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L678 A, P Its mutation influenced the ability of CAPS and RTX to activate TRPV1 without
changing the response of the channel to protons. Its mutation also blunted heat-
induced current responses, with a leftward shift in the temperature threshold.
[166,175]
I679 A Its mutation retained normal sensitivities to CAPS and heat, although it completely
removed their mutual potentiation.
[175]
L681 A The residue is involved in the regulation of permeability of divalent cations, it regulates
the permeability of large cations.
[169,175,178]
M682 A Its mutation caused impaired CAPS- and heat- activation, and significantly reduced
their mutual potentiation.
[175]
E684 G, V Its mutation caused gain of function and strong toxicity when expressed in
Saccharomyces cerevisiae. Its mutation caused significant response to pH 6.4 (threshold
concentration for proton-activation).
[177]
I689 V Its mutation caused gain of function mutation and weaker toxicity when expressed in
Saccharomyces cerevisiae.
[177]
K694 A The residue participates in PIP2 binding. [206]
K698 A The residue participates in PIP2 binding. [206]
Q700 A The residue participates in PIP2 binding. [206]
R701 A The residue participates in PIP2 binding. [191,206]
T704 I The residue is a CaMKII phosphorylation site. PMA decreases the binding of [3H]RTX to
TRPV1 through interaction with this residue. When associated with S502A, its mutation
lost the ability to be activated by CAPS and lost the ability of vanilloid binding.
[46,85,91,115,174]
K710 A, R The residue participates in PIP2 binding. Its mutation caused gain of function and
strong toxicity when expressed in Saccharomyces cerevisiae.
[177,191,206]
Q727 The residue has key roles in heat activation. [191]
F742 S Its mutation caused gain of function and strong toxicity when expressed in
Saccharomyces cerevisiae.
[177]
W752 The residue has key roles in heat activation. [191]
E761 K, Q, Δ Its deletion or mutation blocks RTX binding and proton- and CAPS-induced currents
without affecting TRPV1 activation by heat.
[16,175,176]
K770 A The residue participates in PIP2 binding. [206]
R771 A The residue participates in PIP2 binding. [206]
R778 A The residue has key roles in PIP2 binding. [201,206]
R781 A The residue has key roles in PIP2 binding. [201,206]
R785 A The residue participates in PIP2 binding. [201,206]
W787 R Its mutation caused gain of function and strong toxicity when expressed in
Saccharomyces cerevisiae.
[177]
L792 P Its mutation caused gain of function mutation and weaker toxicity when expressed in
Saccharomyces cerevisiae. Its mutation caused significant response to pH 6.4 (threshold
concentration for proton-activation).
[177]
L796 P, V Its mutation caused gain of function and strong/weaker toxicity when expressed in
Saccharomyces cerevisiae.
[177]
S800 A Its phosphorylation by PKC potentiates CAPS, acid, and thermal responses. [78,85,209]
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directly affect CAPS activation.
ΔG603-S612 reduced the heat response of the channel,
which was not a result of slow gating kinetics, as length-
ening the heat pulse did not yield any increase in the
current amplitude, heat becomes a less effective activator
for the ΔG603-S612 mutant channel.
Cui et al. found that, the turret deletion mutations
ΔG603-G619 and ΔG603-N626 completely disrupted channelfunction; no current could be detected from channel-
expressing cells challenged with either 10 μM CAPS or
high temperatures up to 50°C despite the normal cellular
distribution of the mutant channels similar to that of the
wild type TRPV1 [190].
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